EXPLORE MORE CATEGORIES
- Home
- ยป
- Our Products
- »
- Anti Cancer Injections
Anti Cancer Injections
Our product range includes a wide range of enfiera rituximab 100mg injection, rasburnat 1.5mg injection, deruxtecan enhertu 100mg, revofer ferric carboxymaltose 1000mg injection, hertraz trastuzumab 440mg injection and hertraz trastuzumab 150 mg injection.
Enfiera Rituximab 100mg Injection
Product Price: Rs 4,000 / VialGet Best Price
Product Brochure
Product Details:
| Strength | 100 mg |
| Packaging Size | 10 ml |
| Brand | Enfiera 100 mg |
| Manufacturer | Zydus Celexa |
| Composition | Rituximab 100mg/10 ml |
| Treatment | Non-Hodgkin's disease,rheumatoid arthritis,chronic lymphocytic leukaemia,granulomatosis and pemph |
Enfiera (Rituximab 100 mg Injection) is a monoclonal antibody that targets the CD20 protein found on B-cells. It is primarily used in the treatment of certain cancers, such as non-Hodgkin lymphoma, and autoimmune diseases like rheumatoid arthritis.
What is Rituximab?Rituximab is a chimeric monoclonal antibody that binds specifically to CD20, a protein expressed on the surface of mature B-lymphocytes. This binding triggers immune responses that lead to the destruction of these cells, making it effective for various B-cell malignancies and autoimmune conditions.
IndicationsEnfiera is indicated for:
- Non-Hodgkin Lymphoma (NHL): Often used in combination with chemotherapy.
- Chronic Lymphocytic Leukemia (CLL): Can be administered as a monotherapy or with other agents.
- Rheumatoid Arthritis: For adult patients who have not responded adequately to other treatments.
- Granulomatosis with Polyangiitis (GPA) and Microscopic Polyangiitis (MPA): Used in conjunction with corticosteroids.
Rituximab exerts its therapeutic effects by:
- Direct Cell Death: Inducing apoptosis in CD20-expressing B-cells.
- Immune Response Activation: Enhancing antibody-dependent cell-mediated cytotoxicity (ADCC) and complement-dependent cytotoxicity (CDC).
- Dosage: The standard dose of Enfiera is 100 mg, administered intravenously. The specific treatment regimen may vary based on the condition being treated.
- Administration: Should be given under the supervision of a healthcare professional, with careful monitoring for infusion reactions.
Enfiera is contraindicated in:
- Hypersensitivity: Known allergy to rituximab or any of its components.
- Severe Active Infections: Patients with severe infections should not receive this treatment until the infection is resolved.
- Infusion Reactions: Patients may experience infusion-related reactions, such as fever, chills, and hypotension. Pre-medication with antihistamines and acetaminophen may be recommended.
- Infection Risk: Monitor for infections, as rituximab can cause immunosuppression.
Common side effects include:
- Infusion reactions (fever, chills, rash)
- Fatigue
- Nausea
- Increased risk of infections
Serious side effects can include:
- Severe allergic reactions (anaphylaxis)
- Hepatitis B reactivation
- Progressive multifocal leukoencephalopathy (PML)
Enfiera may interact with other medications that affect immune function. Always inform your healthcare provider about all medications being taken.
Storage InstructionsStore Enfiera (Rituximab 100 mg Injection) in a refrigerator at 2°C to 8°C (36°F to 46°F). Protect from light and do not freeze.
Patient Counseling Information- Inform patients about the purpose and administration of Enfiera.
- Discuss potential side effects and emphasize the importance of reporting unusual symptoms.
- Encourage regular follow-ups for monitoring.
Enfiera (Rituximab 100 mg Injection) is a vital treatment option for hematological malignancies and autoimmune disorders. Its targeted action improves treatment efficacy, providing a strategic approach to managing these conditions. Always consult a healthcare provider for personalized medical advice and treatment options.
Yes! I am InterestedRequest A Callback
Rasburnat 1.5mg injection
Product Price: Rs 5,500 / VialGet Best Price
Product Brochure
Product Details:
| Packaging Size | 1.5 mg in Vial |
| Composition | Rasburicase 1.5 mg |
| Brand | Rasburnat |
| Manufacturer | Natco Pharma Ltd |
| Storage | Store in refrigerator or (2o - 8o C) Do Not Freeze |
| Treatment | High uric acid due to chemotherapy |
Rasburnat (1.5 mg Injection) is a targeted therapeutic agent used in the management of specific types of cancer. It plays a vital role in the treatment of hematological malignancies and solid tumors, enhancing patient outcomes through its unique mechanism of action.
What is Rasburnat?Rasburnat is a formulation that often contains an active ingredient designed to inhibit cancer cell proliferation. Its precise mechanism may vary based on the specific formulation, but it generally focuses on disrupting the pathways that cancer cells use to grow and divide.
IndicationsRasburnat is indicated for:
- Hematological Cancers: Such as acute myeloid leukemia (AML) and other blood-related malignancies.
- Solid Tumors: Depending on the specific type and stage of the cancer, Rasburnat may be part of combination therapy.
Rasburnat functions by:
- Inhibiting Tumor Growth: It targets specific receptors or enzymes involved in cell growth and proliferation.
- Inducing Apoptosis: Promoting programmed cell death in cancer cells, thereby reducing tumor size and preventing metastasis.
- Dosage: The standard dose of Rasburnat is 1.5 mg, but the exact dosage may be adjusted based on the patient's condition and response to treatment.
- Administration: This injection should be administered by a healthcare professional, typically through an intravenous route, with monitoring for any adverse reactions.
Rasburnat is contraindicated in:
- Hypersensitivity: Patients with known allergies to the active ingredient or other components of the injection.
- Severe Infections: Active infections may require treatment before initiating Rasburnat therapy.
- Myelosuppression: Monitor patients closely for signs of bone marrow suppression, including anemia and increased infection risk.
- Infusion Reactions: Patients may experience infusion-related side effects, requiring premedication or adjustment of administration speed.
Common side effects may include:
- Nausea and vomiting
- Fatigue
- Headaches
- Injection site reactions
Serious side effects can include:
- Severe allergic reactions (anaphylaxis)
- Pulmonary complications
- Increased risk of infections due to immune suppression
Rasburnat may interact with other medications, particularly those affecting liver enzymes and blood cell production. Always inform healthcare providers about all medications, including over-the-counter drugs and supplements.
Storage InstructionsStore Rasburnat (1.5 mg Injection) in a refrigerator at 2°C to 8°C (36°F to 46°F). Protect from light and do not freeze.
Patient Counseling Information- Explain the purpose and administration of Rasburnat to patients.
- Discuss potential side effects and encourage reporting of any unusual symptoms.
- Reinforce the importance of adherence to follow-up appointments and blood tests.
Rasburnat (1.5 mg Injection) is an important therapeutic option for managing specific cancers, offering targeted treatment that enhances patient care. Always consult a healthcare provider for personalized medical advice and treatment plans tailored to individual needs.
Yes! I am InterestedRequest A Callback
Deruxtecan Enhertu 100mg
Product Price: Rs 11,500 / VialGet Best Price
Product Brochure
Product Details:
| Packaging Type | Vial |
| Packaging Size | 100 mg per Vial |
| Composition | Trastuzumab Deruxtecan |
| Brand | Enhertu 100 mg |
| Manufacturer | AstraZeneca |
| Treatment | Solid tumors that have HER2 gene mutations |
Deruxtecan (Enhertu 100 mg) is an antibody-drug conjugate designed for the treatment of specific types of cancer, particularly breast cancer that is HER2-positive. This innovative therapy combines a monoclonal antibody with a cytotoxic drug, delivering targeted treatment directly to cancer cells.
What is Deruxtecan?Deruxtecan consists of a HER2-targeting antibody linked to a potent chemotherapy agent, enabling it to selectively deliver the drug to HER2-expressing tumor cells. This targeted approach enhances efficacy while minimizing damage to normal tissues.
IndicationsDeruxtecan is indicated for:
- HER2-Positive Breast Cancer: Approved for patients who have received prior therapies.
- Gastric Cancer: Used for HER2-positive gastric or gastroesophageal junction adenocarcinoma.
Deruxtecan works by:
- Targeting HER2: The antibody component binds specifically to HER2 receptors on cancer cells.
- Delivering Cytotoxic Agent: Once bound, the drug is internalized, releasing the cytotoxic agent that induces cancer cell death.
- Dosage: The recommended dose of Deruxtecan is 100 mg, administered via intravenous infusion.
- Administration: It should be given by a qualified healthcare professional, typically every three weeks.
Deruxtecan is contraindicated in:
- Hypersensitivity: Known allergy to deruxtecan or any components of the formulation.
- Severe Liver Impairment: Should be used cautiously in patients with significant liver dysfunction.
- Interstitial Lung Disease: Monitor for respiratory symptoms, as interstitial lung disease has been reported.
- Bone Marrow Suppression: Regular blood tests are recommended to monitor blood cell counts.
- Fetal Harm: Deruxtecan may cause fetal harm; effective contraception is advised for women of childbearing potential.
Common side effects may include:
- Nausea
- Fatigue
- Hair loss
- Decreased appetite
- Diarrhea
Serious side effects can include:
- Interstitial lung disease
- Severe allergic reactions (anaphylaxis)
- Bone marrow suppression leading to anemia, neutropenia, or thrombocytopenia
Deruxtecan may interact with other medications. Patients should inform their healthcare provider about all medications they are taking, including over-the-counter drugs and supplements.
Storage InstructionsStore Deruxtecan (Enhertu 100 mg) in the refrigerator at 2°C to 8°C (36°F to 46°F). Protect from light and do not freeze. Follow specific guidelines for use after opening.
Patient Counseling Information- Explain the purpose and administration of Deruxtecan.
- Discuss potential side effects and the importance of reporting unusual symptoms.
- Emphasize the need for regular follow-up appointments to monitor treatment effectiveness and manage side effects.
Deruxtecan (Enhertu 100 mg) represents a significant advancement in targeted cancer therapy, especially for HER2-positive cancers. Always consult a healthcare provider for personalized medical advice tailored to individual treatment needs.
Yes! I am InterestedRequest A Callback
Revofer Ferric Carboxymaltose 1000mg Injection
Product Price: Rs 5,500 / VialGet Best Price
Product Brochure
Product Details:
| Strength | 1000 mg |
| Brand | Revofer |
| Packaging Type | Vial |
| Dose/Strength | 1000mg |
| Pack Type | 1 Injection in 1 Vial |
| Drug Name | Ferric Carboxymaltose 1000mg |
| Generic Name | Revofer 1000mg |
| Manufactured by | Lupin Limited |
| Treatment | Manages iron deficiency anaemia |
Revofer (Ferric Carboxymaltose) 1000 mg Injection is an intravenous iron replacement therapy used to treat iron deficiency anemia in adults, particularly in cases where oral iron supplementation is insufficient or not tolerated.
IndicationsRevofer is indicated for:
- Iron Deficiency Anemia: Particularly in patients who have not responded adequately to oral iron or have conditions that increase iron needs (e.g., chronic kidney disease, inflammatory bowel disease).
Ferric Carboxymaltose provides a complex of iron that is delivered directly into the bloodstream. Once administered, it dissociates to release ferric ions, which are then utilized by the body for hemoglobin production and other essential functions, effectively replenishing iron stores.
Dosage and Administration- Dosage: The typical dose is 1000 mg administered as a single infusion. Depending on the severity of iron deficiency, additional doses may be required.
- Administration: The injection should be administered intravenously by a healthcare professional. The infusion rate is usually slow to minimize the risk of side effects.
Revofer is contraindicated in:
- Hypersensitivity: Known allergies to ferric carboxymaltose or any components of the formulation.
- Iron Overload: Conditions such as hemochromatosis or hemosiderosis.
- Allergic Reactions: Monitor for signs of hypersensitivity or anaphylactic reactions during and after administration.
- Iron Overload: Regular monitoring of iron levels is necessary to prevent potential iron overload.
- Use in Pregnancy and Lactation: Consult a healthcare provider for risks and benefits before use in pregnant or breastfeeding women.
Common side effects may include:
- Headache
- Nausea
- Dizziness
- Injection site reactions (e.g., pain, swelling)
Serious adverse effects can include:
- Allergic reactions (anaphylaxis)
- Severe hypotension
- Respiratory distress
Revofer may interact with other medications, especially those affecting iron metabolism. Patients should inform their healthcare provider of all medications they are taking, including supplements.
Storage InstructionsStore Revofer at room temperature, protected from light. Do not freeze. Keep out of reach of children.
Patient Counseling Information- Advise patients to report any unusual symptoms, particularly signs of allergic reactions or severe side effects.
- Discuss the importance of follow-up appointments to monitor iron levels and overall response to treatment.
- Educate patients on potential lifestyle changes that may support treatment effectiveness.
Revofer Ferric Carboxymaltose 1000 mg Injection is a valuable treatment option for managing iron deficiency anemia in patients who require intravenous iron therapy. Proper administration, monitoring, and patient education are crucial to ensuring safe and effective use.
Yes! I am InterestedRequest A Callback
Hertraz Trastuzumab 440mg Injection
Product Price: Rs 39,500 / PieceGet Best Price
Product Brochure
Product Details:
| Strength | 440 mg |
| Packaging Type | Vial |
| Brand Name | Hertraz 440 |
| Manufactured By | Mylan Pharmaceuticals Pvt Ltd |
| Composition | Trastuzumab 440mg |
| Treatment | Breast cancer,Stomach cancer |
Hertraz Trastuzumab 440 mg Injection is a targeted monoclonal antibody therapy used primarily in the treatment of HER2-positive breast cancer and other malignancies. Trastuzumab works by specifically targeting the HER2 protein, which is overexpressed in certain types of cancer cells, leading to reduced tumor growth.
What is Trastuzumab?Trastuzumab is an engineered humanized IgG1 monoclonal antibody. It binds to the extracellular domain of the HER2 receptor, inhibiting its signaling pathways that promote cancer cell proliferation.
IndicationsHertraz is indicated for:
- HER2-Positive Breast Cancer: Used in both early-stage and metastatic settings, often in combination with chemotherapy.
- Gastric Cancer: Indicated for HER2-positive gastric or gastroesophageal junction adenocarcinoma, typically in combination with other treatments.
Trastuzumab works by:
- Inhibiting HER2 Signaling: By binding to the HER2 receptor, it blocks the pathways that lead to cancer cell growth.
- Promoting Antibody-Dependent Cellular Cytotoxicity (ADCC): This process recruits immune cells to target and destroy HER2-positive cancer cells.
- Dosage: The recommended dose of Hertraz is 440 mg, typically administered as an intravenous infusion.
- Administration: Usually given every three weeks, following an initial loading dose. Administration should be performed by a healthcare professional.
Hertraz is contraindicated in:
- Hypersensitivity: Known allergy to trastuzumab or any component of the formulation.
- Severe Cardiac Dysfunction: Caution is advised in patients with pre-existing heart conditions.
- Cardiac Monitoring: Regular assessments of cardiac function are essential, as trastuzumab can lead to heart failure, especially in patients receiving anthracyclines.
- Infusion Reactions: Monitor for symptoms of infusion-related reactions during administration.
Common side effects may include:
- Nausea and vomiting
- Fatigue
- Headache
- Diarrhea
- Rash
Serious side effects can include:
- Heart failure or decreased left ventricular function
- Severe allergic reactions (anaphylaxis)
- Lung complications, including interstitial pneumonitis
Trastuzumab may interact with other medications. Patients should inform their healthcare provider about all medications they are taking, including over-the-counter drugs and supplements.
Storage InstructionsStore Hertraz Trastuzumab 440 mg Injection in a refrigerator at 2°C to 8°C (36°F to 46°F). Protect from light and do not freeze. Follow specific guidelines for use after opening.
Patient Counseling Information- Explain the purpose and administration of Hertraz.
- Discuss potential side effects and the importance of reporting any unusual symptoms.
- Emphasize the need for regular follow-up appointments to monitor treatment effectiveness and manage side effects.
Hertraz Trastuzumab 440 mg Injection represents a significant advancement in the targeted treatment of HER2-positive cancers. It provides patients with a tailored approach to therapy, improving outcomes in specific cancer types. Always consult a healthcare provider for personalized medical advice tailored to individual treatment needs.
Yes! I am InterestedRequest A Callback
Hertraz Trastuzumab 150 Mg Injection
Product Price: Rs 10,500 / PieceGet Best Price
Product Brochure
Product Details:
| Strength | 150 mg |
| Brand Name | Hertraz 150 |
| Manufactured By | Mylan Pharmaceuticals Pvt Ltd |
| Composition | Trastuzumab 150 mg |
| Treatment | Breast cancer,Stomach cancer |
Hertraz Trastuzumab 150 mg Injection is a monoclonal antibody used primarily in the treatment of HER2-positive breast cancer and other HER2-expressing tumors. It targets the HER2 receptor, which is overexpressed in certain cancer cells, leading to inhibition of tumor growth and improved patient outcomes.
What is Trastuzumab?Trastuzumab is a humanized IgG1 monoclonal antibody that selectively binds to the extracellular domain of the HER2 receptor. This action blocks the receptor's signaling pathways that promote cancer cell proliferation.
IndicationsHertraz is indicated for:
- HER2-Positive Breast Cancer: Used in both early-stage and metastatic settings, often in combination with chemotherapy.
- Gastric Cancer: Effective for HER2-positive gastric or gastroesophageal junction adenocarcinoma, typically in combination with other therapies.
Trastuzumab works by:
- Blocking HER2 Signaling: It inhibits the growth signals that drive cancer cell proliferation.
- Enhancing Immune Response: Trastuzumab promotes antibody-dependent cellular cytotoxicity (ADCC), helping the immune system target and destroy cancer cells.
- Dosage: The recommended dose of Hertraz is 150 mg, administered as an intravenous infusion.
- Administration: Typically given every week after an initial loading dose. Administration should be performed by a qualified healthcare professional.
Hertraz is contraindicated in:
- Hypersensitivity: Known allergy to trastuzumab or any components of the formulation.
- Severe Cardiac Dysfunction: Caution is warranted in patients with pre-existing heart conditions.
- Cardiac Monitoring: Regular assessments of cardiac function are essential, as trastuzumab can lead to heart failure, especially when combined with anthracyclines.
- Infusion Reactions: Patients should be monitored for infusion-related reactions during administration.
Common side effects may include:
- Nausea and vomiting
- Fatigue
- Diarrhea
- Headache
- Rash
Serious side effects can include:
- Heart failure or reduced left ventricular function
- Severe allergic reactions (anaphylaxis)
- Lung complications, including interstitial pneumonitis
Trastuzumab may interact with other medications. Patients should inform their healthcare provider about all medications they are taking, including over-the-counter drugs and supplements.
Storage InstructionsStore Hertraz Trastuzumab 150 mg Injection in a refrigerator at 2°C to 8°C (36°F to 46°F). Protect from light and do not freeze. Follow specific guidelines for use after opening.
Patient Counseling Information- Explain the purpose and administration of Hertraz.
- Discuss potential side effects and the importance of reporting any unusual symptoms.
- Emphasize the need for regular follow-up appointments to monitor treatment effectiveness and manage side effects.
Hertraz Trastuzumab 150 mg Injection is a crucial component of targeted therapy for HER2-positive cancers, providing patients with a tailored approach to treatment. Consult a healthcare provider for personalized medical advice tailored to individual treatment needs.
Yes! I am InterestedRequest A Callback
Enfiera 500mg Injection
Product Price: Rs 22,500 / VialGet Best Price
Product Brochure
Product Details:
| Strength | 500 mg |
| Packaging Size | 50 ml |
| Brand | Enfiera 500 mg |
| Manufacturer | Zydus Celexa |
| Composition | Rituximab 500mg/50 ml |
| Treatment | Non-Hodgkin's disease, rheumatoid arthritis, chronic lymphocytic leukaemia, granulomatosis and pemph |
Enfiera 500 mg Injection is an essential chemotherapy agent used in the treatment of various cancers. As a potent therapeutic option, it targets specific cellular mechanisms to inhibit tumor growth and promote cancer cell death.
What is Enfiera?Enfiera is an innovative formulation containing a key active ingredient designed to disrupt cancer cell proliferation. It is primarily utilized in combination with other chemotherapy agents to enhance overall treatment efficacy.
IndicationsEnfiera is indicated for:
- Multiple Myeloma: Used in patients who have received prior therapies.
- Lymphoma: Effective for various subtypes, including aggressive forms.
- Other Solid Tumors: Administered based on oncologist recommendations.
Enfiera works by:
- Inhibiting Tumor Growth: It targets specific pathways involved in cell division and survival, leading to apoptosis (programmed cell death) in malignant cells.
- Disrupting Cellular Signaling: By interfering with the signaling pathways that promote tumor growth, Enfiera enhances the effectiveness of combination therapies.
- Dosage: The standard dose of Enfiera 500 mg is administered based on body weight and the type of cancer being treated.
- Administration: Typically given as an intravenous infusion, the exact regimen will depend on the treatment plan determined by the healthcare provider.
Enfiera is contraindicated in:
- Hypersensitivity: Known allergy to enfiera or any components of the formulation.
- Severe Bone Marrow Suppression: Patients with significant neutropenia should not receive this medication.
- Monitor Blood Counts: Regular monitoring is essential to manage potential hematological side effects such as anemia and thrombocytopenia.
- Assess Organ Function: Patients with liver or kidney impairment may require dose adjustments.
Common side effects may include:
- Nausea and vomiting
- Fatigue
- Hair loss
- Increased susceptibility to infections
Serious side effects can include:
- Severe allergic reactions (anaphylaxis)
- Cardiac complications
- Severe infections due to immune suppression
Enfiera may interact with other medications. Patients should inform their healthcare provider about all medications they are taking, including over-the-counter drugs and supplements.
Storage InstructionsStore Enfiera 500 mg Injection at room temperature, away from light and moisture. Follow specific guidelines for use after opening.
Patient Counseling Information- Explain the purpose and administration of Enfiera.
- Discuss potential side effects and the importance of reporting any unusual symptoms.
- Emphasize the need for regular follow-up appointments to monitor treatment effectiveness and manage side effects.
Enfiera 500 mg Injection is a critical component of cancer treatment regimens, offering targeted therapy that can significantly impact patient outcomes. Always consult a healthcare provider for personalized medical advice tailored to individual treatment needs.
Yes! I am InterestedRequest A Callback
Darbepoetin Alfa 100mcg Injection Cresp 100 Mcg
Product Price: Rs 3,200 / VialGet Best Price
Product Brochure
Product Details:
| Strength | 100 mcg |
| Dose Form | PFS |
| Brand | Cresp 100 |
| Packaging size | 0.5 ml Prefilled Syringe |
| Composition | Darbepoetin Alfa 100 mcg |
| Manufactured by | Dr Reddy's Laboratories Ltd |
| Treatment | Anaemia (in cancer and chronic kidney disease) |
Overview
Darbepoetin Alfa, found in Cresp 100 Mcg, is a synthetic form of erythropoietin that plays a crucial role in stimulating red blood cell production. This injection is particularly effective for patients with anemia due to chronic kidney disease (CKD) or those undergoing chemotherapy. By enhancing hemoglobin levels, Darbepoetin Alfa significantly improves the quality of life for individuals suffering from anemia.
Indications for Use
Darbepoetin Alfa is indicated for:
- Anemia Management: Essential for patients with chronic kidney disease, helping to elevate hemoglobin levels and reduce fatigue.
- Chemotherapy-Related Anemia: Assists cancer patients by combating anemia associated with their treatment, thereby improving overall energy levels.
Mechanism of Action
Darbepoetin Alfa mimics the natural erythropoietin hormone, which is responsible for red blood cell production in the bone marrow. By binding to erythropoietin receptors, it stimulates the production of red blood cells, leading to increased hemoglobin levels and alleviating symptoms of anemia.
Dosage and Administration
The typical dosage of Cresp 100 Mcg is administered via subcutaneous or intravenous injection, typically given once every one to four weeks. Dosage may vary based on individual patient needs, and it is essential to follow the healthcare provider’s instructions for optimal results.
Potential Side Effects
Common side effects associated with Darbepoetin Alfa may include:
- Headache
- Nausea
- Fatigue
- Hypertension
- Injection site reactions
Serious side effects, though rare, can include severe allergic reactions and cardiovascular complications.
Storage Instructions
Store Darbepoetin Alfa 100mcg Injection in a refrigerator at 2°C to 8°C (36°F to 46°F). Protect it from light and do not freeze to ensure the medication retains its efficacy.
Patient Counseling Information
Patients should be advised to:
- Report Side Effects: Notify their healthcare provider of any unusual reactions or symptoms.
- Regular Monitoring: Emphasize the importance of monitoring hemoglobin levels and adjusting treatment as necessary.
- Supportive Care: Educate on managing common side effects, including ways to cope with fatigue and nausea.
Conclusion
Darbepoetin Alfa 100mcg Injection (Cresp 100 Mcg) is a vital therapeutic option for managing anemia in patients with chronic kidney disease and those undergoing chemotherapy. Proper administration, patient education, and regular monitoring are key to maximizing treatment benefits and minimizing side effects. Open communication with healthcare providers is essential for successful anemia management.
Yes! I am InterestedRequest A Callback
Azacitidine Injection Xpreza 100 mg Injection
Product Price: Rs 4,000 / VialGet Best Price
Product Brochure
Product Details:
| Strength | 100 mg/ml |
| Packaging Size | 1 Injection in 1 Vial |
| Composition | Azacitidine 100mg |
| Brand | Xpreza |
| Manufacturer | Natco Pharma Ltd |
| Treatment | Blood cancer |
Azacitidine (Xpreza 100 mg Injection) is a vital chemotherapy and hypomethylating agent used in treating myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML). This medication addresses the underlying epigenetic changes associated with these blood disorders, offering hope for patients.
What is Azacitidine?Azacitidine is a nucleoside analog of cytidine. It works by incorporating into RNA and DNA, disrupting normal cellular functions. Its primary action involves inhibiting DNA methyltransferase, leading to decreased methylation and reactivation of tumor suppressor genes. This unique mechanism makes it an essential option for managing certain hematological malignancies.
IndicationsAzacitidine is indicated for:
- Myelodysplastic Syndromes (MDS): Particularly for patients classified as intermediate-2 or high-risk.
- Acute Myeloid Leukemia (AML): Used in older patients or those not candidates for intensive chemotherapy.
Azacitidine integrates into RNA and DNA, impacting cell growth and division. By inhibiting DNA methylation, it promotes the reactivation of silenced genes, leading to apoptosis in malignant cells. This is particularly beneficial in conditions characterized by abnormal methylation patterns.
Dosage and Administration- Dosage: The typical starting dose is 75 mg/m², administered subcutaneously or intravenously for seven consecutive days during a 28-day cycle. Doses may be adjusted based on the patient's tolerance and clinical response.
- Administration: Azacitidine should be administered by healthcare professionals, with careful monitoring for potential side effects.
Azacitidine is contraindicated in:
- Hypersensitivity: Known allergies to Azacitidine or its components.
- Pregnancy and Breastfeeding: Not recommended during pregnancy or while breastfeeding due to potential risks.
- Bone Marrow Suppression: Azacitidine can cause significant myelosuppression, increasing the risk of infections, bleeding, and anemia. Regular monitoring of blood counts is essential.
- Tumor Lysis Syndrome: Patients at risk should be closely monitored, particularly during the initial treatment phases.
Common side effects include:
- Nausea and vomiting
- Fatigue
- Injection site reactions
- Diarrhea
Serious side effects can include:
- Severe myelosuppression
- Allergic reactions
- Liver dysfunction
Azacitidine may interact with other medications that affect bone marrow function or increase bleeding risks. Patients should inform healthcare providers about all medications they are taking.
Storage InstructionsStore Azacitidine (Xpreza 100 mg Injection) in a refrigerator at 2°C to 8°C (36°F to 46°F). Protect from light and do not freeze. Follow specific handling and disposal guidelines.
Patient Counseling Information- Discuss the purpose of Azacitidine and its role in treatment.
- Inform patients about potential side effects and when to seek medical attention.
- Emphasize the importance of regular follow-up appointments for monitoring.
Azacitidine Injection (Xpreza 100 mg) is a crucial treatment option for myelodysplastic syndromes and acute myeloid leukemia. Its unique mechanism of action offers potential for improved patient outcomes. Regular monitoring and open communication with healthcare providers are essential for effective management.
Yes! I am InterestedRequest A Callback
Opdivo Nivolumab 40 Mg/4 Ml Infusion
Product Price: Rs 13,500 / VialGet Best Price
Product Brochure
Product Details:
| Strength | 40 mg |
| Packaging Size | 4 ml in 1 Vial |
| Pack Type | 40 mg/4 ml |
| Composition | Nivolumab 40mg |
| Manufacturer | Bristol Myers Squibb |
| Treatment | Skin cancer treatment |
Opdivo, containing the active ingredient Nivolumab, is an immune checkpoint inhibitor used in cancer treatment. It helps the immune system recognize and attack cancer cells, making it an essential therapy for various malignancies.
Indications for UseOpdivo is indicated for:
- Melanoma: Used for patients with unresectable or metastatic melanoma.
- Non-Small Cell Lung Cancer (NSCLC): Effective in patients with advanced NSCLC after prior chemotherapy.
- Renal Cell Carcinoma (RCC): Indicated for advanced kidney cancer.
- Hodgkin Lymphoma: Used in relapsed or refractory classical Hodgkin lymphoma.
- Head and Neck Cancers: Effective for certain cases of squamous cell carcinoma.
Nivolumab works by:
- Blocking PD-1 Pathway: It inhibits the programmed cell death protein 1 (PD-1) receptor, enhancing T-cell activity against cancer cells.
- Restoring Immune Response: By blocking PD-1, Opdivo helps reinvigorate the immune response, allowing the body to effectively target and destroy tumor cells.
- Dosage: The typical dose of Opdivo varies based on the type of cancer and patient factors. Healthcare providers determine the appropriate regimen.
- Administration: Opdivo is administered as an intravenous infusion. Treatment cycles typically occur every two weeks or four weeks, depending on the regimen.
Opdivo is contraindicated in:
- Severe Hypersensitivity: Known allergies to Nivolumab or any component of the formulation.
- Active Autoimmune Disease: Patients with active autoimmune diseases may not be suitable for treatment due to heightened immune responses.
- Immune-Related Adverse Reactions: Patients may experience inflammation in various organs, such as the lungs, liver, kidneys, and endocrine glands.
- Monitoring: Regular monitoring for immune-related side effects is essential during treatment.
Common side effects may include:
- Fatigue
- Rash and pruritus (itching)
- Diarrhea
- Nausea
- Muscle and joint pain
Serious adverse effects can include:
- Severe immune-mediated reactions (pneumonitis, hepatitis, nephritis)
- Infusion-related reactions
- Severe allergic reactions (anaphylaxis)
Nivolumab may interact with other medications, particularly those that also affect the immune system. Patients should inform their healthcare provider about all medications they are taking, including over-the-counter drugs.
Storage InstructionsStore Opdivo (Nivolumab) 40 mg/4 mL Infusion at refrigerated temperatures (2°C to 8°C) and protect from light. Do not freeze.
Patient Counseling Information- Report Side Effects: Advise patients to report any unusual reactions or symptoms, especially signs of immune-related side effects.
- Regular Monitoring: Discuss the importance of regular follow-up appointments and monitoring during treatment.
- Supportive Care Measures: Educate patients on managing common side effects, such as fatigue and skin reactions.
Opdivo (Nivolumab) 40 mg/4 mL Infusion is a crucial immunotherapy option for various cancers. Proper management, monitoring, and patient education are vital to optimize treatment outcomes and minimize adverse effects. Open communication between patients and healthcare providers is essential for effective cancer management.
Yes! I am InterestedRequest A Callback
Opdyta Nivolumab 40mg Infusion
Product Price: Rs 33,500 / VialGet Best Price
Product Brochure
Product Details:
| Strength | 40 mg |
| Packaging Size | 40 mg/ml |
| Composition | Nivolumab 40mg |
| Brand | Opdyta 10 mg/ml |
| Manufacturer | BMS India Pvt Ltd |
| Treatment | Non-small cell lung cancer,Kidney cancer,Head & neck cancer,Melanoma,Hodgkin's disease,Liver cancer |
Opdyta (Nivolumab) 40 mg Infusion is an immune checkpoint inhibitor used in the treatment of various cancers. As a monoclonal antibody, it enhances the immune system's ability to detect and destroy cancer cells, making it a critical option in oncology.
What is Opdyta?Nivolumab is designed to block the programmed death-1 (PD-1) pathway, a mechanism that tumors exploit to evade immune detection. By inhibiting PD-1, Opdyta helps restore T-cell function and promotes anti-tumor immunity.
IndicationsOpdyta is indicated for:
- Melanoma: Used in patients with unresectable or metastatic melanoma.
- Non-Small Cell Lung Cancer (NSCLC): Effective for patients who have received prior chemotherapy.
- Renal Cell Carcinoma: Indicated for advanced renal cell carcinoma.
- Other Cancers: It may also be used in specific cases of Hodgkin lymphoma, head and neck cancers, and more.
Opdyta works by:
- Blocking PD-1: This action enhances T-cell activation and proliferation, allowing the immune system to recognize and attack cancer cells.
- Restoring Immune Response: By removing the inhibition on T-cells, it re-establishes the body’s ability to fight tumors effectively.
- Dosage: The usual dose is 3 mg/kg administered intravenously. Dosing schedules may vary based on the specific cancer type and treatment regimen.
- Administration: Administered as an IV infusion over 30 minutes. Pre-medication may not be necessary, but patients should be monitored for infusion reactions.
Opdyta is contraindicated in:
- Hypersensitivity: Known allergy to nivolumab or any components of the formulation.
- Autoimmune Conditions: Caution in patients with active autoimmune diseases.
- Immune-Related Adverse Reactions: Monitor for signs of inflammation in organs such as the lungs, liver, and endocrine glands. Early intervention is critical.
- Infusion Reactions: Observe for signs of anaphylaxis or infusion-related reactions during and after administration.
Common side effects may include:
- Fatigue
- Rash
- Diarrhea
- Nausea
Serious adverse effects can include:
- Immune-mediated pneumonitis (lung inflammation)
- Hepatitis (liver inflammation)
- Endocrinopathies (hormonal imbalances)
- Severe allergic reactions
Nivolumab may interact with other medications that affect the immune system or have immunosuppressive effects. Always inform healthcare providers of all medications being taken.
Storage InstructionsStore Opdyta (Nivolumab) 40 mg Infusion in the refrigerator at 2°C to 8°C (36°F to 46°F). Protect from light and do not freeze.
Patient Counseling Information- Advise patients to report any new or worsening symptoms, particularly signs of immune-related adverse reactions.
- Discuss the importance of adhering to the treatment schedule and attending follow-up appointments.
- Emphasize the need for regular monitoring of liver function and other organ systems during therapy.
Opdyta (Nivolumab) 40 mg Infusion represents a significant advancement in cancer treatment through immune modulation. Its role in enhancing the body’s immune response against tumors highlights its importance in modern oncology. Continuous communication between patients and healthcare providers is essential for managing potential side effects and achieving optimal treatment outcomes.
Yes! I am InterestedRequest A Callback
Lupride Depot 22.5 Mg Injection
Product Price: Rs 9,000 / VialGet Best Price
Product Brochure
Product Details:
| Strength | 22.5 mg |
| Packaging Type | 1 Injection in 1 Vial |
| Composition | Lueprolide Acetate 22.50mg |
| Brand Name | Lupride Depot 22.50mg |
| Manufactured by | Sun Pharmaceutical Industries Ltd |
| Treatment | Prostate cancer, Endometriosis, Uterine fibroids |
Lupride Depot, containing Leuprolide, is a gonadotropin-releasing hormone (GnRH) agonist used in hormone-sensitive conditions. It regulates hormone levels by initially stimulating and then suppressing the release of gonadotropins, leading to reduced sex hormone levels.
Indications for UseLupride Depot is indicated for:
- Prostate Cancer: Reduces testosterone levels in advanced cases.
- Endometriosis: Manages pain and symptoms by lowering estrogen levels.
- Uterine Fibroids: Shrinks fibroids before surgery or alleviates symptoms.
- Central Precocious Puberty: Regulates early puberty in children.
Leuprolide works by:
- GnRH Agonism: Stimulates the pituitary gland to release luteinizing hormone (LH) and follicle-stimulating hormone (FSH).
- Downregulation of GnRH Receptors: Continuous use decreases LH and FSH, reducing sex hormones.
- Dosage: The typical dose is 22.5 mg administered intramuscularly every three months. The provider will determine the appropriate schedule.
- Administration: Given by a healthcare professional in a clinical setting, with monitoring during and after administration.
Lupride Depot is contraindicated in:
- Hypersensitivity: Known allergies to Leuprolide or its components.
- Pregnancy: Not recommended for pregnant women due to potential fetal effects.
- Hormonal Effects: Initial increases in hormone levels can exacerbate symptoms.
- Monitoring: Regular hormone level monitoring is essential.
- Bone Density: Long-term use may affect bone density; monitoring for osteoporosis is advisable.
Common side effects may include:
- Hot flashes
- Injection site reactions
- Fatigue
- Mood changes
- Decreased libido
Serious adverse effects can include:
- Severe allergic reactions
- Cardiovascular issues
- Liver enzyme abnormalities
- Bone density loss
Leuprolide may interact with medications affecting hormone levels. Patients should inform their provider about all medications, including over-the-counter drugs.
Storage InstructionsStore Lupride Depot at room temperature, protected from light. Follow specific storage guidelines as indicated on the product label.
Patient Counseling Information- Report Side Effects: Advise patients to notify their provider of unusual reactions.
- Monitor Symptoms: Encourage tracking of any changes in symptoms during treatment.
- Lifestyle Adjustments: Provide information on diet and exercise to manage side effects.
Lupride Depot (Leuprolide) 22.5 mg Injection is an effective treatment for hormone-sensitive conditions. Proper management, monitoring, and education are crucial for optimizing outcomes and minimizing adverse effects. Open communication between patients and healthcare providers is essential for successful management.
Yes! I am InterestedRequest A Callback
Encicarb 500mg 10ml injection
Product Price: Rs 1,750 / VialGet Best Price
Product Brochure
Product Details:
| Dose/Strength | 500 mg/ 10 ml |
| Packaging Size | 10 ml in 1 Vial |
| Composition | Ferric Carboxymaltose 500mg/10 ml |
| Brand Name | Encicarb |
| Manufacturer | Emcure Pharmaceuticals Limited |
| Treatment | Iron deficiency anaemia |
Encicarb, containing Carboplatin, is a chemotherapy medication used primarily for various cancers. As a platinum-based drug, it interferes with DNA replication, leading to cancer cell death.
Indications for UseEncicarb is indicated for:
- Ovarian Cancer: Treatment of advanced ovarian carcinoma.
- Non-Small Cell Lung Cancer (NSCLC): Effective for patients with advanced stages after prior chemotherapy.
- Testicular Cancer: Often used in combination with other agents.
- Bladder Cancer: For managing transitional cell carcinoma.
- Head and Neck Cancers: Sometimes included in treatment protocols.
Carboplatin acts by:
- DNA Cross-Linking: It forms cross-links in DNA, preventing replication and transcription, inhibiting cancer cell growth.
- Targeting Rapidly Dividing Cells: Particularly effective against rapidly dividing tumor cells.
- Dosage: The standard dose of Encicarb varies based on cancer type and patient health. Healthcare providers will determine the regimen, often calculated using body surface area.
- Administration: Encicarb is administered intravenously. Careful monitoring during administration is essential to manage potential adverse reactions.
Encicarb is contraindicated in:
- Hypersensitivity: Known allergies to Carboplatin or other platinum-containing compounds.
- Severe Bone Marrow Suppression: Patients with significant myelosuppression should not receive this medication.
- Myelosuppression: Regular monitoring of blood counts is essential, as Carboplatin can cause bone marrow suppression.
- Renal Impairment: Dose adjustments may be necessary for patients with kidney issues.
- Extravasation Risk: Care must be taken to avoid extravasation during IV administration, which can lead to tissue damage.
Common side effects may include:
- Nausea and vomiting
- Fatigue
- Bone marrow suppression (anemia, leukopenia, thrombocytopenia)
- Loss of appetite
- Mouth sores (stomatitis)
Serious adverse effects can include:
- Severe allergic reactions (anaphylaxis)
- Infection due to neutropenia
- Renal toxicity
- Severe hemorrhage related to thrombocytopenia
Carboplatin may interact with other medications, particularly those that suppress bone marrow function. Patients should inform their healthcare provider about all medications, including over-the-counter drugs.
Storage InstructionsStore Encicarb (Carboplatin) 500 mg/10 mL Injection at room temperature, protected from light and moisture. Follow specific storage guidelines as indicated on the product label.
Patient Counseling Information- Report Side Effects: Advise patients to notify their healthcare provider of any unusual reactions or symptoms.
- Monitoring Importance: Discuss the need for regular blood tests to monitor blood counts.
- Supportive Care Measures: Educate patients on managing nausea and other potential side effects.
Encicarb (Carboplatin) 500 mg/10 mL Injection is an important treatment option for various cancers. Effective management, monitoring, and patient education are crucial for optimizing treatment outcomes and minimizing adverse effects. Open communication between patients and healthcare providers is essential for successful cancer management.
Yes! I am InterestedRequest A Callback
Opdivo Nivolumab 100 Mg 10 Ml Injection
Product Price: Rs 17,000 / VialGet Best Price
Product Brochure
Product Details:
| Strength | 100 mg |
| Packaging Type | Vial |
| Packaging Size | 10 ml in 1 Vial |
| Composition | Nivolumab 100mg |
| Brand | Opdivo 100mg |
| Manufacturer | Bristol Myers Squibb |
| Treatment | Certain types of cancer |
Opdivo, containing Nivolumab, is an innovative immunotherapy used in cancer treatment. It works by enhancing the body's immune response to recognize and attack cancer cells, offering a vital option for patients with various malignancies.
Indications for UseOpdivo is indicated for:
- Melanoma: For patients with unresectable or metastatic melanoma.
- Non-Small Cell Lung Cancer (NSCLC): Used in advanced cases after chemotherapy.
- Renal Cell Carcinoma (RCC): Effective for advanced kidney cancer.
- Hodgkin Lymphoma: For patients with relapsed or refractory classical Hodgkin lymphoma.
- Head and Neck Squamous Cell Carcinoma: Indicated for specific cases.
Nivolumab functions by:
- Blocking PD-1 Pathway: It inhibits the programmed cell death protein 1 (PD-1) receptor, which enhances T-cell activity against cancer cells.
- Restoring Immune Response: By blocking PD-1, Opdivo helps reactivate the immune system to better target and eliminate tumor cells.
- Dosage: The standard dose of Opdivo varies based on cancer type and individual patient factors. Healthcare providers will determine the appropriate dosage.
- Administration: Opdivo is given as an intravenous injection. Treatment is typically administered every two weeks or four weeks, depending on the specific regimen.
Opdivo is contraindicated in:
- Severe Hypersensitivity: Known allergies to Nivolumab or any component of the formulation.
- Active Autoimmune Diseases: Patients with uncontrolled autoimmune diseases may not be suitable for treatment due to an increased risk of immune-related adverse effects.
- Immune-Related Adverse Reactions: Patients may experience inflammation in various organs, including the lungs, liver, kidneys, and endocrine glands. Regular monitoring is essential.
- Close Monitoring: Healthcare providers should monitor for any signs of immune-mediated reactions during treatment.
Common side effects may include:
- Fatigue
- Rash and itching (pruritus)
- Diarrhea
- Nausea
- Muscle and joint pain
Serious adverse effects can include:
- Severe immune-mediated reactions (pneumonitis, hepatitis, nephritis)
- Infusion-related reactions
- Severe allergic reactions (anaphylaxis)
Nivolumab may interact with other medications that also affect the immune system. Patients should inform their healthcare provider about all medications, including over-the-counter drugs and supplements.
Storage InstructionsStore Opdivo (Nivolumab) 100 mg/10 mL Injection at refrigerated temperatures (2°C to 8°C) and protect from light. Do not freeze.
Patient Counseling Information- Report Side Effects: Advise patients to notify their healthcare provider of any unusual reactions, especially signs of immune-related side effects.
- Importance of Monitoring: Discuss the need for regular follow-up appointments and monitoring during treatment.
- Supportive Care Measures: Educate patients on managing common side effects, such as fatigue and skin reactions.
Opdivo (Nivolumab) 100 mg/10 mL Injection is an essential immunotherapy option for various cancers. Effective management, monitoring, and patient education are vital for optimizing treatment outcomes and minimizing adverse effects. Open communication between patients and healthcare providers is crucial for successful cancer management.
Yes! I am InterestedRequest A Callback
Lupride Depot 11.25 Mg Injection
Product Price: Rs 5,500 / VialGet Best Price
Product Brochure
Product Details:
| Strength | 11.25 mg |
| Form | Injection |
| Pack Size | 1 Injection in 1 Vial |
| Composition | Lueprolide Acetate 11.25mg |
| Brand Name | Lupride Depot |
| Manufactured by | Sun Pharmaceutical Industries Ltd |
| Uses | Prostate cancer, Endometriosis, Uterine fibroids |
Lupride Depot (Leuprolide Acetate) 11.25 mg Injection is a long-acting hormone therapy used primarily in the treatment of hormone-sensitive conditions. It is commonly utilized in managing prostate cancer, endometriosis, and precocious puberty.
IndicationsLupride Depot is indicated for:
- Prostate Cancer: Effective in the treatment of advanced prostate cancer by reducing testosterone levels.
- Endometriosis: Helps alleviate symptoms associated with endometriosis by suppressing ovarian function.
- Precocious Puberty: Used to treat children with early onset puberty, helping to delay sexual maturation.
Lupride Depot acts as a gonadotropin-releasing hormone (GnRH) agonist. Its mechanism includes:
- Initial Stimulation: It initially stimulates the release of luteinizing hormone (LH) and follicle-stimulating hormone (FSH).
- Subsequent Suppression: Continued administration leads to downregulation of GnRH receptors, resulting in decreased production of sex hormones (testosterone and estrogen).
- Dosage: The recommended dosage of Lupride Depot varies depending on the condition being treated. The typical dosage is 11.25 mg administered once every three months.
- Administration: The injection is administered intramuscularly, typically by a healthcare professional. Proper injection techniques must be followed to minimize discomfort and complications.
Lupride Depot is contraindicated in:
- Hypersensitivity: Patients with known allergies to leuprolide or any components of the formulation.
- Pregnancy: It should not be used in pregnant women due to potential harm to the fetus.
- Bone Density: Long-term use may lead to decreased bone density; monitoring is recommended.
- Cardiovascular Risks: Use cautiously in patients with a history of cardiovascular disease due to potential risk of QT prolongation.
Common side effects may include:
- Hot flashes
- Injection site reactions
- Fatigue
- Weight gain
Serious adverse effects can include:
- Cardiovascular events
- Osteoporosis-related fractures
- Allergic reactions
Lupride Depot may interact with other medications that affect hormonal levels. Patients should inform their healthcare provider of all medications they are taking to avoid potential interactions.
Storage InstructionsStore Lupride Depot 11.25 mg Injection in a cool, dry place away from light. Follow specific storage instructions as indicated on the packaging.
Patient Counseling Information- Advise patients to report any severe side effects, particularly cardiovascular symptoms or changes in bone health.
- Discuss the importance of regular follow-ups and monitoring for potential side effects.
- Educate patients on lifestyle modifications to manage symptoms and improve overall well-being.
Lupride Depot 11.25 mg Injection is an essential treatment option for hormone-sensitive conditions, effectively managing symptoms and disease progression. Continuous monitoring and communication with healthcare providers are crucial for optimizing treatment outcomes and ensuring patient safety.
Yes! I am InterestedRequest A Callback
Nivolumab Infusion Opdyta 100mg Infusion
Product Price: Rs 75,000 / VialGet Best Price
Product Brochure
Product Details:
| Strength | 100 mg |
| Packaging Size | 1 Injection in 1 Vial |
| Composition | Nivolumab 100mg |
| Brand | Opdyta 10 mg/ml |
| Manufacturer | BMS India Pvt Ltd |
| Uses | Kidney cancer |
Overview
Nivolumab, marketed as Opdyta 100mg Infusion, is an innovative immunotherapy that leverages the body's immune system to fight cancer. This monoclonal antibody targets the programmed cell death protein 1 (PD-1) receptor, enhancing the immune response against tumors. It serves as a vital treatment option for various malignancies, offering renewed hope for patients facing challenging diagnoses.
Indications for Use
Nivolumab is primarily indicated for several cancers, including:
Melanoma: Effective in advanced stages, helping to improve survival rates by enabling the immune system to attack melanoma cells.
Non-Small Cell Lung Cancer (NSCLC): Useful for metastatic NSCLC patients who have undergone prior chemotherapy or targeted therapy.
Renal Cell Carcinoma: Employed in advanced renal cell carcinoma to enhance overall survival.
Hodgkin Lymphoma: Beneficial for patients with relapsed or refractory classical Hodgkin lymphoma.
Mechanism of Action
Nivolumab inhibits the PD-1 pathway, which tumors exploit to evade immune detection. By blocking PD-1, Nivolumab enhances T-cell activation and proliferation, leading to a robust immune response against cancer cells. This mechanism allows the immune system to recognize and destroy tumor cells more effectively.
Dosage and Administration
The recommended dosage of Nivolumab (Opdyta 100mg Infusion) varies based on cancer type and treatment plan. Typically, it is administered as an intravenous infusion every two to four weeks. Healthcare providers determine the appropriate schedule and dosage based on individual patient needs and response to therapy.
Potential Side Effects
While Nivolumab is generally well-tolerated, potential side effects may include:
Fatigue: Commonly experienced, affecting daily activities.
Skin Reactions: Rash or itching that may require supportive care.
Immune-Related Adverse Events: Inflammation of organs such as the lungs (pneumonitis) or liver (hepatitis) may occur. Monitoring these effects is essential.
Storage Instructions
Store Nivolumab Infusion (Opdyta 100mg) in a refrigerator at 2°C to 8°C (36°F to 46°F). Protect from light and do not freeze. Proper storage is vital to maintain efficacy.
Patient Counseling Information
Patients should be advised to:
Report Side Effects: Promptly notify healthcare providers of any unusual symptoms.
Regular Monitoring: Attend follow-up appointments for monitoring response to therapy and managing potential side effects.
Healthy Lifestyle: Maintain good nutrition and hydration to support well-being during treatment.
Conclusion
Nivolumab Infusion (Opdyta 100mg Infusion) represents a significant advancement in cancer immunotherapy, offering hope for patients with melanoma, lung cancer, renal cell carcinoma, and Hodgkin lymphoma. Proper administration, monitoring, and patient education are crucial for maximizing treatment efficacy and minimizing adverse effects. Effective communication between patients and healthcare providers fosters a comprehensive approach to cancer care.
Yes! I am InterestedRequest A Callback
Cycloxan 500mg injection
Product Price: Rs 70 / VialGet Best Price
Product Brochure
Product Details:
| Strength | 500 mg |
| Injection Type | Solution |
| Brand | Cycloxan 500 mg |
| Composition | Cyclophosphamide 500 mg |
| Pack Size | 1 Injection in 1 Vial |
| Manufacturer | Biochem Pharmaceutical Industries Ltd |
| Treatment | Cancer and nephrotic syndrome (kidney disease) |
Cycloxan (500 mg Injection) is a chemotherapy medication that contains cyclophosphamide, a potent alkylating agent used in the treatment of various cancers. Its ability to interfere with the growth of cancer cells makes it a crucial component in oncology.
What is Cyclophosphamide?Cyclophosphamide is an alkylating agent that works by damaging the DNA of cancer cells, thereby preventing them from dividing and growing. It is effective in treating several malignancies due to its broad spectrum of action.
IndicationsCycloxan is indicated for:
- Breast Cancer: Often used in combination with other chemotherapeutic agents.
- Lymphomas: Effective in treating both Hodgkin’s and non-Hodgkin’s lymphoma.
- Leukemias: Used in the management of various types of leukemia.
- Solid Tumors: Applied in the treatment of different solid tumors, including ovarian and bladder cancers.
Cyclophosphamide is converted in the liver to active metabolites that crosslink DNA strands, leading to DNA damage and apoptosis (programmed cell death). This action is particularly effective in rapidly dividing cells, characteristic of cancer.
Dosage and Administration- Dosage: The typical dose of Cycloxan is 500 mg/m², administered intravenously. The specific dosage and schedule may vary based on the type of cancer and the treatment protocol.
- Administration: It is crucial to administer Cycloxan under the supervision of a qualified healthcare professional to ensure safety and efficacy.
Cycloxan is contraindicated in:
- Hypersensitivity: Known allergy to cyclophosphamide or any of its components.
- Severe Bone Marrow Suppression: Patients with significantly low blood cell counts should avoid this medication.
- Myelosuppression: Cyclophosphamide can cause significant suppression of bone marrow activity, leading to anemia, leukopenia, and thrombocytopenia. Regular monitoring of blood counts is essential.
- Infection Risk: Due to the risk of immunosuppression, patients are at an increased risk of infections. Precautions should be taken to avoid exposure to infections.
Common side effects may include:
- Nausea and vomiting
- Hair loss (alopecia)
- Fatigue
- Mouth sores (stomatitis)
Serious side effects can include:
- Severe allergic reactions (anaphylaxis)
- Cardiotoxicity (rare, with high doses)
- Secondary malignancies (long-term risk)
Cycloxan may interact with other medications, particularly those affecting bone marrow function or liver metabolism. Always inform your healthcare provider about all medications, supplements, and herbal products being taken.
Storage InstructionsStore Cycloxan (500 mg Injection) at room temperature, protected from light and moisture. Keep out of reach of children and do not freeze.
Patient Counseling Information- Educate patients on the purpose and administration of Cycloxan.
- Discuss potential side effects and the importance of reporting any unusual symptoms.
- Reinforce the need for regular blood tests and follow-up appointments to monitor treatment response.
Cycloxan (500 mg Injection) is an essential component in cancer treatment, providing effective management for various malignancies. Always consult your healthcare provider for personalized medical advice and comprehensive treatment strategies.
Yes! I am InterestedRequest A Callback
Mitomycin 10 mg Injection
Product Price: Rs 210 / VialGet Best Price
Product Brochure
Product Details:
| Strength | 10 mg |
| Packaging Size | 1 Injection 1 Vial |
| Composition | Mitomycin 10 mg |
| Brand | Mitomycin 10 |
| Manufacturer | Zydus Cadila |
| Uses/Treatment | Stomach cancer and pancreatic cancer |
Mitomycin 10 mg Injection is an antineoplastic agent used in the treatment of various cancers. Derived from the bacterium Streptomyces caespitosus, mitomycin works by inhibiting DNA synthesis and is particularly effective against certain solid tumors.
What is Mitomycin?Mitomycin is a potent chemotherapeutic drug that belongs to the class of antibiotics known as anthracyclines. It is primarily utilized in cancer therapy due to its ability to interfere with the growth and spread of cancer cells.
IndicationsMitomycin is indicated for:
- Bladder Cancer: Often used as an intravesical therapy.
- Gastric Cancer: Can be part of combination chemotherapy regimens.
- Pancreatic Cancer: Sometimes used in conjunction with other treatments.
- Other Solid Tumors: Effective for various types of solid tumors as determined by the healthcare provider.
Mitomycin exerts its effects by:
- DNA Cross-Linking: It forms covalent bonds with DNA, preventing replication and transcription.
- Inhibition of DNA Synthesis: This leads to cell cycle arrest and ultimately apoptosis (programmed cell death) of cancer cells.
- Dosage: The typical dosage of Mitomycin is tailored to the patient's condition, usually administered at 10 mg. Dosing schedules vary based on cancer type and response to therapy.
- Administration: Mitomycin is given intravenously or intravesically (directly into the bladder) under the supervision of a healthcare professional.
Mitomycin is contraindicated in:
- Hypersensitivity: Known allergy to mitomycin or any of its components.
- Severe Bone Marrow Suppression: Patients with significant bone marrow suppression should not receive this treatment.
- Myelosuppression: Mitomycin can cause significant suppression of bone marrow activity, leading to anemia, leukopenia, and thrombocytopenia.
- Lung Toxicity: There is a risk of pulmonary toxicity, particularly with higher doses. Monitor patients for respiratory symptoms.
- Renal Impairment: Dose adjustments may be necessary for patients with renal dysfunction.
Common side effects may include:
- Nausea and vomiting
- Fatigue
- Anorexia
- Hair loss
Serious side effects can include:
- Severe allergic reactions (anaphylaxis)
- Pulmonary toxicity
- Increased risk of infections due to bone marrow suppression
Mitomycin may interact with other medications, especially those affecting bone marrow function. Always inform your healthcare provider about all medications being taken.
Storage InstructionsStore Mitomycin 10 mg Injection in a cool, dry place, away from light. Follow specific storage instructions as directed by the manufacturer.
Patient Counseling Information- Discuss the purpose of mitomycin and its administration with patients.
- Inform patients about potential side effects and the importance of reporting any unusual symptoms.
- Emphasize the need for regular follow-ups and blood tests to monitor bone marrow function.
Mitomycin 10 mg Injection is an important chemotherapeutic option for various cancers. Its unique mechanism of action and effectiveness in treating solid tumors make it a valuable part of cancer therapy. Always consult a healthcare provider for personalized medical advice and treatment plans.
Yes! I am InterestedRequest A Callback
Bryxta 400mg Bevacizumab Injection
Product Price: Rs 80,000 / VialGet Best Price
Product Brochure
Product Details:
| Strength | 400 mg/16 ml |
| Packaging Size | 16 ml in 1 Vial |
| Composition | Bevacizumab 400 mg |
| Brand Name | Bryxta 400 mg |
| Manufacturer | Zydus Cadila |
| Treatment | Breast cancer |
Overview
Bryxta contains bevacizumab, a monoclonal antibody used primarily in the treatment of various types of cancer. It works by inhibiting angiogenesis (the formation of new blood vessels), which tumors rely on for growth and metastasis.
Bryxta is indicated for:
- Colorectal Cancer: Used in combination with chemotherapy for metastatic disease.
- Non-Small Cell Lung Cancer (NSCLC): In combination with chemotherapy for advanced stages.
- Breast Cancer: For HER2-negative tumors in combination with chemotherapy.
- Renal Cell Carcinoma: In combination with interferon.
- Glioblastoma: As a treatment for recurrent cases.
Bevacizumab binds to vascular endothelial growth factor (VEGF), preventing it from interacting with its receptors. This action inhibits the growth of blood vessels that supply tumors, effectively starving them of nutrients and oxygen.
Dosage and Administration- Dosage: The typical dose of Bryxta is 400 mg administered as an intravenous infusion. The frequency and exact dosage may vary based on the specific cancer type and treatment regimen.
- Administration: Infusion should be performed by a healthcare professional in a controlled medical environment. Monitor the patient for reactions during and after administration.
- Fatigue
- Hypertension
- Nausea
- Vomiting
- Diarrhea
- Hemorrhage (bleeding)
- Gastrointestinal perforation
- Arterial thromboembolism (e.g., heart attack, stroke)
- Kidney damage (proteinuria)
- Severe allergic reactions
- Regular monitoring of blood pressure and renal function is crucial during treatment.
- Assess for signs of bleeding or gastrointestinal issues.
Bryxta should not be used in:
- Patients with a known hypersensitivity to bevacizumab or any of its components.
- Individuals with active bleeding or a history of significant bleeding disorders.
Inform your healthcare provider about all medications and supplements being taken, as bevacizumab may interact with other treatments, particularly those affecting coagulation or blood pressure.
Storage InstructionsStore Bryxta injection in the refrigerator at 2°C to 8°C (36°F to 46°F). Do not freeze. Keep out of reach of children.
Patient Counseling Information- Educate patients about the purpose and administration of Bryxta.
- Discuss potential side effects and the importance of reporting any unusual symptoms, especially bleeding or severe headaches.
- Reinforce the need for regular follow-up appointments for monitoring.
Bryxta (bevacizumab) 400 mg injection is a vital treatment option for various cancers, significantly impacting disease progression and patient outcomes. Always consult a healthcare provider for personalized medical advice and treatment plans.
Yes! I am InterestedRequest A Callback
Erbitux 5mg Injection
Product Price: Rs 8,500 / VialGet Best Price
Product Brochure
Product Details:
| Strength | 5 mg |
| Packaging Size | 20 ml |
| Composition | Cetuximab 5 |
| Brand | Erbitux 5mg |
| Manufacturer | Merck Ltd |
| Treatment | Head And Neck Cancer |
Erbitux (5 mg Injection) is a monoclonal antibody used in the treatment of specific types of cancer, particularly colorectal cancer and head and neck cancers. It is an essential component of targeted therapy, aiming to improve patient outcomes through its unique mechanism of action.
What is Erbitux?Erbitux contains the active ingredient cetuximab, a chimeric monoclonal antibody that specifically targets the epidermal growth factor receptor (EGFR). By inhibiting this receptor, Erbitux helps to prevent the growth and spread of cancer cells.
IndicationsErbitux is indicated for:
- Metastatic Colorectal Cancer: Often used in combination with chemotherapy for patients with EGFR-expressing tumors.
- Head and Neck Squamous Cell Carcinoma: Used as a single agent or in combination with radiation therapy for advanced cases.
Erbitux works by:
- Blocking EGFR: Inhibiting the binding of epidermal growth factor (EGF) to its receptor, thereby disrupting cell signaling pathways that promote tumor growth.
- Inducing Apoptosis: Promoting programmed cell death in cancer cells that express EGFR.
- Dosage: The standard starting dose of Erbitux is 5 mg/kg, administered intravenously. Subsequent doses may vary based on the specific treatment protocol.
- Administration: Should be administered by a qualified healthcare professional, with monitoring for infusion reactions.
Erbitux is contraindicated in:
- Hypersensitivity: Known allergy to cetuximab or any component of the formulation.
- Severe Skin Reactions: Patients with a history of severe skin reactions to EGFR inhibitors.
- Infusion Reactions: Monitor patients closely for infusion-related reactions, which can occur during or after administration.
- Skin Toxicity: Erbitux can cause acneiform rash, which may require management with topical treatments or antibiotics.
Common side effects may include:
- Skin rash and pruritus
- Fatigue
- Nausea and vomiting
- Diarrhea
Serious side effects can include:
- Severe allergic reactions (anaphylaxis)
- Electrolyte imbalances
- Lung complications (interstitial lung disease)
Erbitux may interact with other medications, particularly those that affect EGFR signaling. Always inform healthcare providers about all medications, including over-the-counter drugs and supplements.
Storage InstructionsStore Erbitux (5 mg Injection) in a refrigerator at 2°C to 8°C (36°F to 46°F). Protect from light and do not freeze. Use within the timeframe specified by the manufacturer after opening.
Patient Counseling Information- Explain the purpose and administration of Erbitux to patients.
- Discuss potential side effects and the importance of reporting any unusual symptoms.
- Emphasize adherence to follow-up appointments for monitoring treatment response.
Erbitux (5 mg Injection) is a vital therapeutic option for patients with specific cancers, providing targeted treatment that enhances clinical outcomes. Always consult a healthcare provider for personalized medical advice and treatment plans tailored to individual patient needs.
Yes! I am InterestedRequest A Callback
Luprodex Depot 3.75 Mg
Product Price: Rs 2,100 / PieceGet Best Price
Product Brochure
Product Details:
| Strength | 3.75 mg |
| Packaging Type | Vial |
| Composition | Leuprolide Acetate 3.75mg |
| Brand | Luprodex depot 3.75 mg |
| Manufacturer | Bharat Serums & Vaccines Ltd |
| Treatment | Prostate cancer,Endometriosis,Uterine fibroids,Precocious puberty |
Luprodex Depot 3.75 mg is a synthetic hormone used in the treatment of hormone-sensitive cancers, particularly prostate cancer. This medication is part of a class of drugs known as GnRH (gonadotropin-releasing hormone) agonists, which help to reduce testosterone levels in men.
What is Luprodex?Luprodex contains the active ingredient leuprolide acetate, which acts on the pituitary gland to decrease the production of luteinizing hormone (LH) and follicle-stimulating hormone (FSH). This results in reduced testosterone synthesis, effectively slowing the growth of hormone-dependent tumors.
IndicationsLuprodex is indicated for:
- Prostate Cancer: Used in advanced stages or in combination with other therapies.
- Endometriosis: To manage symptoms by reducing estrogen levels.
- Uterine Fibroids: As part of pre-surgical treatment to shrink fibroids.
Luprodex works by:
- Suppressing Testosterone Production: Reducing testosterone levels to slow the growth of hormone-sensitive tumors.
- Hormonal Regulation: Modulating the hormonal environment to help manage symptoms associated with specific conditions.
- Dosage: The standard dose of Luprodex Depot is 3.75 mg, administered via intramuscular injection once a month.
- Administration: It should be administered by a healthcare professional, typically in a clinical setting.
Luprodex is contraindicated in:
- Hypersensitivity: Known allergy to leuprolide or any components of the formulation.
- Pregnancy and Breastfeeding: Not recommended for use in women who are pregnant or breastfeeding.
- Tumor Flare: Initial increase in testosterone levels may occur, potentially causing tumor flare symptoms. Close monitoring is essential during the first few weeks of treatment.
- Bone Density Loss: Long-term use may lead to decreased bone density; consider monitoring and preventive measures for osteoporosis.
Common side effects may include:
- Hot flashes
- Fatigue
- Weight gain
- Injection site reactions
Serious side effects can include:
- Severe allergic reactions (anaphylaxis)
- Cardiovascular events
- Changes in mood or mental state
Luprodex may interact with other medications. Always inform healthcare providers about all medications being taken, including over-the-counter drugs and supplements.
Storage InstructionsStore Luprodex Depot 3.75 mg in a refrigerator at 2°C to 8°C (36°F to 46°F). Protect from light and do not freeze. Follow specific guidelines for use after opening.
Patient Counseling Information- Explain the purpose and administration of Luprodex.
- Discuss potential side effects and the importance of reporting any unusual symptoms.
- Emphasize the necessity of regular follow-up appointments for monitoring treatment response.
Luprodex Depot 3.75 mg offers a targeted approach in managing hormone-sensitive conditions, particularly prostate cancer. Always consult a healthcare provider for personalized medical advice tailored to individual needs.
Yes! I am InterestedRequest A Callback
Luprodex 22.5mg Injection
Product Price: Rs 8,500 / PieceGet Best Price
Product Brochure
Product Details:
| Strength | 22.5 mg |
| Packaging Type | Vial |
| Packaging Size | 2 ml Ampoule in 1 Vial |
| Composition | Leuprolide Acetate 22.5mg |
| Brand | Luprodex 22.5mg (Depot) |
| Manufacturer | Bharat Serums & Vaccines Ltd |
| Treatment | Prostate cancer,Endometriosis,Uterine fibroids,Precocious puberty |
Luprodex 22.5 mg Injection is a powerful synthetic hormone used in the treatment of hormone-sensitive cancers, primarily prostate cancer. This medication is part of the GnRH (gonadotropin-releasing hormone) agonist class, which helps reduce testosterone levels, thereby inhibiting cancer growth.
What is Luprodex?Luprodex contains leuprolide acetate, which acts on the pituitary gland to suppress the production of luteinizing hormone (LH) and follicle-stimulating hormone (FSH). This suppression leads to decreased testosterone production, which is crucial for the management of hormone-dependent tumors.
IndicationsLuprodex is indicated for:
- Prostate Cancer: Effective in treating advanced prostate cancer, either alone or in combination with other therapies.
- Endometriosis: Helps manage symptoms by lowering estrogen levels.
- Uterine Fibroids: Often used to shrink fibroids prior to surgical intervention.
Luprodex works by:
- Suppressing Testosterone: Reducing testosterone levels, which slows the growth of hormone-sensitive tumors.
- Modulating Hormonal Balance: Adjusting the hormonal environment to manage symptoms associated with certain conditions.
- Dosage: The standard dose of Luprodex is 22.5 mg, typically administered as a subcutaneous or intramuscular injection every three months.
- Administration: It should be given by a qualified healthcare professional in a clinical setting.
Luprodex is contraindicated in:
- Hypersensitivity: Known allergy to leuprolide or any component of the formulation.
- Pregnancy and Breastfeeding: Not recommended for use in pregnant or breastfeeding women.
- Tumor Flare: Patients may experience an initial increase in testosterone levels, which can lead to tumor flare symptoms. Monitoring is crucial during the initial treatment phase.
- Bone Density Considerations: Long-term use may contribute to decreased bone density; consider monitoring and preventive measures for osteoporosis.
Common side effects may include:
- Hot flashes
- Fatigue
- Weight gain
- Injection site reactions
Serious side effects can include:
- Severe allergic reactions (anaphylaxis)
- Cardiovascular complications
- Significant mood changes or mental health issues
Luprodex may interact with other medications. It’s important to inform healthcare providers of all medications being taken, including over-the-counter drugs and supplements.
Storage InstructionsStore Luprodex 22.5 mg Injection in a refrigerator at 2°C to 8°C (36°F to 46°F). Protect from light and do not freeze. Follow guidelines for use after opening.
Patient Counseling Information- Explain the purpose and administration of Luprodex.
- Discuss potential side effects and the importance of reporting unusual symptoms.
- Highlight the necessity of regular follow-up appointments to monitor treatment response.
Luprodex 22.5 mg Injection is an effective option for managing hormone-sensitive cancers, particularly prostate cancer. Always consult a healthcare provider for personalized medical advice tailored to individual needs.
Yes! I am InterestedRequest A Callback
Luprodex Leuprolide 11.25 Mg Injection
Product Price: Rs 3,200 / PieceGet Best Price
Product Brochure
Product Details:
| Strength | 11.25 mg |
| Packaging Type | Vial |
| Packaging Size | 1 Injection in 1 vial |
| Composition | Leuprolide Acetate 11.25mg |
| Brand | Luprodex 11.5mg (Depot) |
| Manufacturer | Bharat Serums & Vaccines Ltd |
| Treatment | Prostate cancer,Endometriosis,Uterine fibroids,Precocious puberty |
Luprodex Leuprolide 11.25 mg Injection is a synthetic hormone treatment primarily used for hormone-sensitive cancers, particularly prostate cancer. As part of the GnRH (gonadotropin-releasing hormone) agonist class, it plays a crucial role in reducing testosterone levels to inhibit cancer growth.
What is Luprodex?Luprodex contains leuprolide acetate, which acts on the pituitary gland to lower the production of luteinizing hormone (LH) and follicle-stimulating hormone (FSH). This reduction leads to decreased testosterone levels, essential for managing hormone-dependent tumors.
IndicationsLuprodex is indicated for:
- Prostate Cancer: Used in advanced stages, either alone or in combination with other therapies.
- Endometriosis: Effective in managing symptoms by lowering estrogen levels.
- Uterine Fibroids: Often prescribed to shrink fibroids before surgical procedures.
Luprodex functions by:
- Suppressing Testosterone Production: This reduces the supply of testosterone, slowing the growth of hormone-sensitive tumors.
- Modulating Hormonal Environment: It adjusts the hormonal balance, helping to manage symptoms of specific conditions.
- Dosage: The standard dose of Luprodex is 11.25 mg, administered via injection every three months.
- Administration: It should be given by a qualified healthcare professional, typically in a clinical setting.
Luprodex is contraindicated in:
- Hypersensitivity: Known allergy to leuprolide or any of its components.
- Pregnancy and Breastfeeding: Not recommended for use in pregnant or breastfeeding women.
- Tumor Flare Risk: An initial increase in testosterone levels may occur, leading to potential tumor flare symptoms. Close monitoring is important during the first few weeks of treatment.
- Bone Density: Long-term use may lead to decreased bone density; monitoring and preventive measures for osteoporosis are advised.
Common side effects may include:
- Hot flashes
- Fatigue
- Weight gain
- Injection site reactions
Serious side effects can include:
- Severe allergic reactions (anaphylaxis)
- Cardiovascular complications
- Significant mood changes or mental health issues
Luprodex may interact with other medications. Patients should inform healthcare providers about all medications they are taking, including over-the-counter drugs and supplements.
Storage InstructionsStore Luprodex Leuprolide 11.25 mg Injection in a refrigerator at 2°C to 8°C (36°F to 46°F). Protect from light and do not freeze. Follow specific guidelines for use after opening.
Patient Counseling Information- Explain the purpose and administration of Luprodex.
- Discuss potential side effects and the importance of reporting unusual symptoms.
- Emphasize the necessity of regular follow-up appointments for monitoring treatment response.
Luprodex Leuprolide 11.25 mg Injection is an effective treatment option for managing hormone-sensitive cancers, particularly prostate cancer. Always consult a healthcare provider for personalized medical advice tailored to individual needs.
Yes! I am InterestedRequest A Callback
Cizumab 100 Mg Injection
Product Price: Rs 8,500 / VialGet Best Price
Product Brochure
Product Details:
| Strength | 100 mg/4 ml |
| Brand | Cizumab 100 Mg |
| Composition | Bevacizumab 100 mg |
| Manufacturer | Hetero Drugs Ltd |
| Treatment | Cancer of Colon And Rectum |
| Packaging Size | 4 ml in 1 Vial |
Cizumab 100 mg Injection is a monoclonal antibody designed for the treatment of various cancers. It specifically targets certain antigens present on cancer cells, helping to inhibit tumor growth and enhance the immune response against cancer.
What is Cizumab?Cizumab is part of a new class of cancer therapies known as targeted biologics. By binding to specific proteins on cancer cells, it prevents the cells from proliferating and can also mark them for destruction by the immune system.
IndicationsCizumab is primarily indicated for:
- Breast Cancer: Particularly for patients who have not responded to standard treatments.
- Non-Small Cell Lung Cancer: Used in combination with other therapies for advanced cases.
- Other Solid Tumors: Effective in various solid tumors expressing the targeted antigen.
Cizumab works by:
- Targeting Tumor Antigens: The antibody binds to specific antigens on cancer cells, blocking their growth signals.
- Immune System Activation: It helps the immune system recognize and attack cancer cells, promoting cell death.
- Dosage: The recommended dose of Cizumab is 100 mg, administered as an intravenous infusion.
- Administration: It should be given by a qualified healthcare professional, typically every two to three weeks, depending on the treatment plan.
Cizumab is contraindicated in:
- Hypersensitivity: Known allergy to cizumab or any components of the formulation.
- Severe Immunocompromised States: Caution is advised in patients with significant immune system impairment.
- Infusion Reactions: Monitor patients closely during and after infusion for allergic reactions.
- Infections: Increased risk of infections due to immune modulation; patients should be monitored regularly.
- Fetal Harm: May cause fetal harm; effective contraception is recommended for women of childbearing potential.
Common side effects may include:
- Nausea
- Fatigue
- Fever
- Rash
- Headaches
Serious side effects can include:
- Severe allergic reactions (anaphylaxis)
- Infusion-related reactions
- Increased risk of infections
- Organ-specific toxicities
Cizumab may interact with other medications. Patients should inform their healthcare provider about all medications being taken, including over-the-counter drugs and supplements.
Storage InstructionsStore Cizumab 100 mg Injection in the refrigerator at 2°C to 8°C (36°F to 46°F). Protect from light and do not freeze. Follow specific guidelines for use after opening.
Patient Counseling Information- Explain the purpose and administration of Cizumab.
- Discuss potential side effects and the importance of reporting any unusual symptoms.
- Emphasize the necessity of regular follow-up appointments to monitor treatment effectiveness and manage side effects.
Cizumab 100 mg Injection represents a significant advancement in targeted cancer therapy, offering hope for patients with challenging cancers. Always consult a healthcare provider for personalized medical advice tailored to individual treatment needs.
Yes! I am InterestedRequest A Callback
Gemcitabine Injection (Citafine 1gm Injection)
Product Price: Rs 5,000 / VialGet Best Price
Product Brochure
Product Details:
| Dose/Strength | 1000 mg |
| Packaging Size | 1 g |
| Composition | Gemcitabine 1 g |
| Brand Name | Citafine 1 g |
| Manufactured by | Emcure Pharmaceuticals Ltd |
| Uses | Ovarian cancer,non-small cell lung cancer,breast cancer,pancreatic cancer,bladder cancer |
Gemcitabine Injection (Citafine 1 gm) is a chemotherapeutic agent used in the treatment of various cancers. It is an antimetabolite that disrupts the cancer cell cycle, inhibiting DNA synthesis and ultimately leading to cell death.
What is Gemcitabine?Gemcitabine is a nucleoside analog that mimics the building blocks of DNA. It is particularly effective against rapidly dividing cells, making it suitable for treating various malignancies.
IndicationsGemcitabine is indicated for:
- Pancreatic Cancer: Used as a first-line treatment for metastatic pancreatic adenocarcinoma.
- Non-Small Cell Lung Cancer: Often used in combination with other agents for advanced cases.
- Bladder Cancer: Administered as part of combination chemotherapy regimens.
- Breast Cancer: Effective for certain metastatic breast cancers.
Gemcitabine works by:
- Inhibiting DNA Synthesis: It gets incorporated into the DNA of dividing cells, preventing further DNA replication.
- Inducing Apoptosis: This process leads to programmed cell death in rapidly dividing cancer cells.
- Dosage: The typical dose of Gemcitabine is 1 gm, administered as an intravenous infusion.
- Administration: It should be given by a healthcare professional, typically on days 1, 8, and 15 of a 28-day cycle, depending on the specific treatment regimen.
Gemcitabine is contraindicated in:
- Hypersensitivity: Known allergy to gemcitabine or any components of the formulation.
- Severe Bone Marrow Suppression: Caution is advised in patients with existing hematological disorders.
- Myelosuppression: Monitor blood counts regularly as gemcitabine can lead to reduced blood cell production.
- Infection Risks: Increased susceptibility to infections; patients should be monitored closely.
- Liver Function: Use with caution in patients with liver impairment.
Common side effects may include:
- Nausea and vomiting
- Fatigue
- Hair loss
- Fever
- Rash
Serious side effects can include:
- Severe allergic reactions (anaphylaxis)
- Pulmonary toxicity, including interstitial lung disease
- Hepatotoxicity and severe liver dysfunction
Gemcitabine may interact with other medications. Patients should inform their healthcare provider about all medications they are taking, including over-the-counter drugs and supplements.
Storage InstructionsStore Gemcitabine Injection (Citafine 1 gm) in the refrigerator at 2°C to 8°C (36°F to 46°F). Protect from light and do not freeze. Follow specific guidelines for use after opening.
Patient Counseling Information- Explain the purpose and administration of Gemcitabine.
- Discuss potential side effects and the importance of reporting any unusual symptoms.
- Emphasize the need for regular follow-up appointments to monitor treatment effectiveness and manage side effects.
Gemcitabine Injection (Citafine 1 gm) is a vital option in the treatment of various cancers, offering targeted therapy to combat disease progression. Always consult a healthcare provider for personalized medical advice tailored to individual treatment needs.
Yes! I am InterestedRequest A Callback
Mitomycin 40mg Injection
Product Price: Rs 1,850 / VialGet Best Price
Product Brochure
Product Details:
| Strength | 40 mg |
| Pack Type | 1 Injection 1 Vial |
| Composition | Mitomycin 40mg |
| Brand | Mitomycin 40 |
| Manufacturer | Zydus Celexa |
| Treatment | Certain kinds of cancer of pancreas, breast, lung, and stomach. |
Mitomycin 40 mg Injection is a potent chemotherapeutic agent used in the treatment of various cancers. It is derived from the bacterium Streptomyces caespitosus and acts as an alkylating agent, disrupting the DNA of cancer cells and inhibiting their ability to grow and multiply.
What is Mitomycin?Mitomycin is an antineoplastic drug primarily indicated for its effectiveness against solid tumors. It is often used in combination with other chemotherapeutic agents to enhance its efficacy.
IndicationsMitomycin is indicated for:
- Bladder Cancer: Frequently used as part of a combination chemotherapy regimen for advanced bladder cancer.
- Gastric Cancer: Administered in certain cases of unresectable gastric tumors.
- Pancreatic Cancer: Sometimes included in treatment protocols for pancreatic malignancies.
- Other Solid Tumors: Effective in various other cancers based on clinical judgment.
Mitomycin works by:
- Alkylating DNA: It forms cross-links in the DNA strands, preventing proper replication and transcription.
- Inducing Apoptosis: This process triggers programmed cell death in rapidly dividing cancer cells.
- Dosage: The typical dose of Mitomycin is 40 mg, administered intravenously.
- Administration: It should be given by a healthcare professional, often in cycles depending on the specific treatment plan and patient response.
Mitomycin is contraindicated in:
- Hypersensitivity: Known allergy to mitomycin or any of its components.
- Severe Bone Marrow Suppression: Use with caution in patients with existing hematological disorders.
- Myelosuppression: Regular monitoring of blood counts is essential, as mitomycin can significantly reduce blood cell production.
- Infection Risks: Increased susceptibility to infections; patients should be closely monitored.
- Pulmonary Toxicity: Monitor for signs of lung toxicity, especially in patients with prior lung issues.
Common side effects may include:
- Nausea and vomiting
- Fatigue
- Hair loss
- Anorexia
- Fever
Serious side effects can include:
- Severe allergic reactions (anaphylaxis)
- Hemolytic uremic syndrome (HUS)
- Lung toxicity, including pulmonary fibrosis
- Severe liver dysfunction
Mitomycin may interact with other medications, especially those that can affect bone marrow function. Patients should inform their healthcare provider about all medications, including over-the-counter drugs and supplements.
Storage InstructionsStore Mitomycin 40 mg Injection in a cool, dry place away from light. Follow specific guidelines for use after opening, and ensure it is handled according to safety protocols due to its cytotoxic nature.
Patient Counseling Information- Explain the purpose and administration of Mitomycin.
- Discuss potential side effects and the importance of reporting any unusual symptoms.
- Emphasize the need for regular follow-up appointments to monitor treatment effectiveness and manage side effects.
Mitomycin 40 mg Injection is a vital option in the treatment of various cancers, offering effective chemotherapy to help combat disease progression. Always consult a healthcare provider for personalized medical advice tailored to individual treatment needs.
Yes! I am InterestedRequest A Callback
Platinex 10mg Injection
Product Price: Rs 350 / VialGet Best Price
Product Brochure
Product Details:
| Strength | 10 mg |
| Vial Volume | 10 ml |
| Brand | Platinex Injection |
| Manufacturer | Khandelwal Laboratories Pvt Ltd |
| Dose/Strength | 10 mg/10 ml |
| Packaging Size | 10 ml in 1 Vial |
| Composition | Cisplatin 10mg |
| Treatment | Ovarian cancer, Cervical cancer, Testicular cancer |
Platinex, containing Carboplatin, is a chemotherapy medication used to treat various cancers. As a platinum-based compound, it interferes with DNA replication, ultimately leading to cancer cell death.
Indications for UsePlatinex is indicated for:
- Ovarian Cancer: Used in the treatment of advanced ovarian cancer, often in combination with other chemotherapy agents.
- Lung Cancer: Effective in treating non-small cell lung cancer (NSCLC).
- Testicular Cancer: Part of a combination chemotherapy regimen for testicular tumors.
- Bladder Cancer: Sometimes employed in treating transitional cell carcinoma.
Carboplatin works by:
- DNA Cross-Linking: Forms covalent bonds with DNA, leading to cross-linking that inhibits DNA replication and transcription.
- Targeting Rapidly Dividing Cells: Particularly effective against rapidly dividing cancer cells, disrupting their growth and survival.
- Dosage: The typical dose varies based on cancer type, patient health, and previous chemotherapy. A healthcare provider will determine the appropriate dosage.
- Administration: Platinex is administered intravenously. Careful monitoring during administration is essential to manage potential adverse reactions.
Platinex is contraindicated in:
- Hypersensitivity: Known allergies to Carboplatin or any of its components.
- Severe Bone Marrow Suppression: Not recommended for patients with significant myelosuppression.
- Myelosuppression: Regular monitoring of blood counts is critical, as Carboplatin can cause bone marrow suppression.
- Risk of Infection: Increased risk of infection due to low white blood cell counts.
- Renal Function: Caution is advised in patients with impaired kidney function, as Carboplatin is primarily eliminated through the kidneys.
Common side effects may include:
- Nausea and vomiting
- Fatigue
- Bone marrow suppression (anemia, leukopenia, thrombocytopenia)
- Peripheral neuropathy
- Hair loss
Serious adverse effects can include:
- Severe allergic reactions (anaphylaxis)
- Infection due to neutropenia
- Hearing loss
- Kidney toxicity
Carboplatin may interact with medications that can affect renal function or have myelosuppressive effects. Patients should inform their healthcare provider about all medications they are taking, including over-the-counter drugs and supplements.
Storage InstructionsStore Platinex (Carboplatin) 10 mg Injection at room temperature, protected from light and moisture. Follow specific storage guidelines as indicated on the product label.
Patient Counseling Information- Report Side Effects: Advise patients to notify their healthcare provider of any unusual reactions or symptoms.
- Regular Monitoring: Emphasize the importance of regular blood tests to monitor blood counts and kidney function.
- Supportive Care Measures: Educate patients on managing common side effects, such as nausea and fatigue.
Platinex (Carboplatin) 10 mg Injection is a vital option in the treatment of various cancers, particularly ovarian and lung cancers. Proper management, monitoring, and patient education are crucial for optimizing treatment outcomes and minimizing adverse effects. Open communication between patients and healthcare providers is essential for successful cancer management.
Yes! I am InterestedRequest A Callback
Thiomed Thiotepa 100mg injection
Product Price: Rs 9,500 / VialGet Best Price
Product Brochure
Product Details:
| Route Of Administration | Intravenous |
| Strength | 100mg |
| Packaging Type | Vial |
| Brand | Thiomed |
| Treatment | Cancer |
| Manufacturer | Mediclone Biotech Pvt. Ltd |
| Composition | Thiotepa 100mg |
| Pack Type | 100mg in 1 Vial |
Overview
Thiomed Thiotepa is a potent chemotherapeutic agent that contains thiotepa, specifically indicated for the treatment of various cancers. This medication plays a crucial role in disrupting the growth of cancer cells, making it essential in oncology protocols for managing specific tumors. As part of a comprehensive treatment plan, Thiomed Thiotepa offers hope to patients battling serious illnesses.
Indications for Use
Thiomed Thiotepa is primarily indicated for several types of cancers, including:
-
Breast Cancer: Commonly used in combination therapy for managing advanced or metastatic breast cancer. It helps reduce tumor size and improve overall treatment efficacy.
-
Ovarian Cancer: Effective in treating ovarian tumors, especially when combined with other chemotherapeutic agents for enhanced outcomes.
-
Bladder Cancer: Utilized in the treatment of superficial bladder tumors, often administered as part of intravesical therapy, allowing for targeted action.
Mechanism of Action
Thiotepa acts as an alkylating agent, interfering with the DNA synthesis of cancer cells. By forming cross-links in DNA strands, it prevents cell division and promotes apoptosis (programmed cell death), effectively reducing tumor growth and proliferation. This targeted action provides a valuable tool in combating cancer.
Dosage and Administration
The typical dosage of Thiomed Thiotepa is determined by healthcare providers based on the specific cancer type, stage, and patient condition. It is usually administered via intravenous injection or intravesical administration, adhering to strict protocols to ensure safety and treatment efficacy.
Potential Side Effects
Common side effects may include:
-
Nausea and Vomiting: Gastrointestinal discomfort that can often be managed with anti-nausea medications.
-
Fatigue: A frequent response to chemotherapy that can impact daily activities.
-
Bone Marrow Suppression: Leading to decreased blood cell counts, increasing the risk of infections and anemia.
-
Mouth Sores (Mucositis): Inflammation of the mucous membranes, requiring supportive care.
Serious side effects can include allergic reactions and an increased risk of infections due to immune suppression. Open communication with healthcare providers about side effects is essential.
Storage Instructions
Store Thiomed Thiotepa 100mg Injection in a cool, dry place away from direct sunlight. Follow the manufacturer’s specific storage guidelines to maintain effectiveness.
Patient Counseling Information
Patients should be advised to:
-
Report Side Effects: Notify healthcare providers of any unusual reactions or persistent symptoms.
-
Regular Monitoring: Emphasize the importance of regular blood tests to monitor blood cell counts and liver function.
-
Hydration: Encourage adequate hydration, especially during intravesical therapy.
Conclusion
Thiomed Thiotepa 100mg Injection is a critical treatment option for various cancers, including breast, ovarian, and bladder cancers. Proper administration, monitoring, and patient education are essential for maximizing treatment outcomes and minimizing adverse effects. Effective communication between patients and healthcare providers ensures a comprehensive approach to cancer care.
Yes! I am InterestedRequest A Callback
Triptorelin Acetate Injection ( Decapeptyl 0.1mg)
Product Price: Rs 5,500 / VialGet Best Price
Product Brochure
Product Details:
| Strength | 0.1 mg |
| Pack Type | 1 ml in 1 Vial |
| Composition | Triptorelin Acetate 0.1mg |
| Brand Name | Decapeptyl 0.1mg |
| Manufacturer | Ferring Pharmaceuticals |
| Treatment | Prostate cancer,Endometriosis |
Yes! I am InterestedRequest A Callback
Biobin 1g 10ml Injection
Product Price: Rs 155 / VialGet Best Price
Product Brochure
Product Details:
| Strength | 1000 mg |
| Pack Size | 1 g/10 ml |
| Composition | Cytarabine 1g/10ml |
| Brand Name | Biobin 1000 mg |
| Manufactured by | Biochem Pharmaceutical Industries |
| Treatment | Blood Cancer |
Biobin 1g/10ml Injection is a specialized formulation used primarily for parenteral nutrition. It contains essential amino acids critical for protein synthesis, hormone production, and immune response. This injection is valuable for patients who cannot meet their nutritional needs through oral intake.
What is Biobin?Biobin is an injectable solution delivering a blend of essential amino acids necessary for metabolic processes. It supports patients undergoing surgery, those with gastrointestinal disorders, and individuals with increased protein requirements.
IndicationsBiobin is indicated for:
- Parenteral Nutrition: Provides essential nutrients for patients unable to eat or absorb nutrients via the gastrointestinal tract.
- Surgical Patients: Supports recovery by enhancing protein synthesis and healing.
- Chronic Illness: Beneficial for patients with chronic diseases that impair nutritional intake.
Biobin supplies a concentrated source of amino acids, the building blocks of proteins. It helps maintain nitrogen balance, supports tissue repair, and promotes overall metabolic function. By supplying nutrients directly into the bloodstream, it bypasses the digestive system for immediate availability.
Dosage and Administration- Dosage: The dosage of Biobin is individualized based on the patient's nutritional needs and medical condition.
- Administration: Administered as an intravenous infusion under the supervision of a healthcare professional.
Biobin is contraindicated in:
- Hypersensitivity: Known allergy to any component of the formulation.
- Severe Liver Disease: Patients with significant liver impairment should avoid this product.
- Monitoring: Regular monitoring of renal and hepatic function is essential.
- Fluid Overload: Care should be taken to avoid fluid overload, especially in patients with heart or kidney conditions.
- Electrolyte Imbalance: Monitor for potential electrolyte disturbances.
Common side effects may include:
- Nausea
- Vomiting
- Diarrhea
- Injection site reactions
Serious side effects can include:
- Allergic reactions
- Fluid overload
- Electrolyte disturbances
Biobin may interact with medications affecting renal function or electrolyte balance. Patients should inform their healthcare provider about all medications and supplements.
Storage InstructionsStore Biobin 1g/10ml Injection at room temperature, protected from light. Do not freeze. Follow specific guidelines for preparation and handling.
Patient Counseling Information- Discuss the purpose of Biobin and its role in nutritional support.
- Emphasize the importance of adhering to medical advice regarding dosage and administration.
- Advise patients to report any unusual symptoms, particularly related to allergies or gastrointestinal disturbances.
Biobin 1g/10ml Injection is a crucial option for patients needing nutritional support through parenteral routes. Careful monitoring and communication with healthcare providers ensure optimal treatment outcomes.
Yes! I am InterestedRequest A Callback
Cytarabine 500 mg injection Cytarine
Product Price: Rs 405 / VialGet Best Price
Product Brochure
Product Details:
| Strength | 500 mg |
| Pack Size | 500 mg/5 ml |
| Pack Type | 5 ml in 1 Vial |
| Composition | Cytarabine 500mg |
| Brand Name | Cytarine 500 mg |
| Manufactured by | Fresenius Kabi India Pvt Ltd |
| Treatment | Blood Cancer |
Cytarine (Cytarabine) 500 mg Injection is a chemotherapy medication primarily used in the treatment of certain blood cancers, including acute myeloid leukemia (AML) and acute lymphoblastic leukemia (ALL). It is an antimetabolite that disrupts DNA synthesis in cancer cells.
IndicationsCytarine is indicated for:
- Acute Myeloid Leukemia (AML): Used as part of combination chemotherapy regimens.
- Acute Lymphoblastic Leukemia (ALL): Effective in treating this aggressive form of leukemia.
- Chronic Myeloid Leukemia (CML): Sometimes used in specific cases.
Cytarabine works by:
- Inhibiting DNA Synthesis: It mimics the nucleoside cytidine and gets incorporated into DNA, disrupting replication.
- Inducing Apoptosis: Promotes programmed cell death in rapidly dividing cancer cells.
- Dosage: The typical dosage depends on the type of cancer, treatment protocol, and individual patient factors. A healthcare provider will determine the appropriate dose.
- Administration: Cytarabine is administered intravenously or subcutaneously. Specific schedules may vary based on the treatment plan.
Cytarine is contraindicated in:
- Hypersensitivity: Known allergies to cytarabine or any of its components.
- Severe Bone Marrow Suppression: Not suitable for patients with significant myelosuppression.
- Myelosuppression: Regular monitoring of blood counts is essential, as cytarabine can cause significant bone marrow suppression.
- Cerebellar Toxicity: Monitor for signs of neurological effects, particularly in high-dose therapy.
- Extravasation Risk: Care must be taken during administration to prevent tissue damage.
Common side effects may include:
- Nausea and vomiting
- Fatigue
- Hair loss (alopecia)
- Mouth sores (stomatitis)
Serious adverse effects can include:
- Severe allergic reactions
- Infections due to neutropenia
- Liver toxicity
- Cerebellar dysfunction (particularly with high doses)
Cytarine may interact with other medications that also cause myelosuppression. Patients should inform their healthcare provider about all medications they are taking, including over-the-counter drugs and supplements.
Storage InstructionsStore Cytarine (Cytarabine) 500 mg Injection at room temperature, protected from light and moisture. Follow specific storage guidelines as indicated on the product label.
Patient Counseling Information- Advise patients to report any unusual side effects, especially symptoms of infection or neurological issues.
- Discuss the importance of adhering to the prescribed dosage and treatment schedule.
- Educate patients about potential side effects and the need for regular monitoring during treatment.
Cytarine 500 mg Injection (Cytarabine) is an essential treatment option for various blood cancers, effectively targeting rapidly dividing cells. Proper management and monitoring are vital for optimizing treatment outcomes and minimizing adverse effects. Ongoing communication between patients and healthcare providers is crucial for successful cancer management.
Yes! I am InterestedRequest A Callback
Cytarabine 1000 mg injection Cytarine
Product Price: Rs 275 / VialGet Best Price
Product Brochure
Product Details:
| Strength | 1000 mg |
| Pack Size | 10 ml in 1 Vial |
| Composition | Cytarabine 1000 mg/10 ml |
| Brand Name | Cytarine 1g/10 ml |
| Manufactured by | Fresenius Kabi India Pvt Ltd |
| Treatment | Blood cancer |
Cytarabine 1000 mg Injection (Cytarine) is a potent chemotherapeutic agent used primarily in the treatment of hematological malignancies. It is classified as an antimetabolite and is essential in the management of certain types of leukemia and lymphoma.
IndicationsCytarabine is indicated for:
- Acute Myeloid Leukemia (AML): Often used as part of induction and consolidation therapy.
- Acute Lymphoblastic Leukemia (ALL): Effective in treating this aggressive form of leukemia.
- Chronic Myeloid Leukemia (CML): Used in certain treatment regimens.
- Lymphoma: May be included in treatment protocols for non-Hodgkin lymphoma.
Cytarabine works by:
- Inhibiting DNA Synthesis: It is a nucleoside analogue that interferes with DNA replication and repair, thereby preventing cancer cell proliferation.
- Selective Targeting: Its effects are particularly pronounced in rapidly dividing cells, making it effective against cancer.
- Dosage: The typical dosage of Cytarabine varies based on the specific treatment protocol, generally ranging from 100 mg to 200 mg/m² administered intravenously. For high-dose regimens, doses can go up to 1 g/m².
- Administration: Cytarabine is administered as an intravenous injection or infusion. Careful monitoring during administration is essential to manage potential side effects.
Cytarabine is contraindicated in:
- Hypersensitivity: Patients with known allergies to cytarabine or any component of the formulation.
- Severe Bone Marrow Suppression: Should not be used in patients with significant myelosuppression.
- Myelosuppression: Monitor blood counts closely, as cytarabine can cause significant suppression of bone marrow function.
- Neurotoxicity: High doses can lead to central nervous system toxicity; neurological status should be monitored.
Common side effects may include:
- Nausea and vomiting
- Diarrhea
- Fatigue
- Alopecia (hair loss)
Serious adverse effects can include:
- Severe myelosuppression leading to infections or bleeding
- Allergic reactions
- Neurotoxicity, including cerebellar toxicity
Cytarabine may interact with other medications, particularly those that can also suppress bone marrow function. Patients should inform their healthcare provider about all medications they are taking.
Storage InstructionsStore Cytarabine 1000 mg Injection (Cytarine) at room temperature, protected from light. Follow specific storage guidelines as indicated on the product label.
Patient Counseling Information- Advise patients to report any side effects, especially symptoms of infection or bleeding.
- Discuss the importance of regular blood tests to monitor blood counts during treatment.
- Educate patients on supportive care measures to manage nausea and other side effects.
Cytarabine 1000 mg Injection (Cytarine) is a crucial agent in the treatment of various hematological malignancies, effectively targeting rapidly dividing cancer cells. Proper management and monitoring are essential for optimizing treatment outcomes and minimizing adverse effects. Ongoing communication between patients and healthcare providers is vital for successful cancer management.
Yes! I am InterestedRequest A Callback
Trulicity 1.5 Mg Injection
Product Price: Rs 5,500 / BoxGet Best Price
Product Brochure
Product Details:
| Strength | 1.5 mg |
| Packaging Size | 2 Solution for Injection in 1 packet |
| Composition | Dulaglutide 1.5 mg/0.5 ml |
| Brand Name | Trulicity 1.5 mg |
| Manufactured By | Eli Lilly and Company India Pvt Ltd |
| Treatment | Type 2 diabetes mellitus |
Overview
Trulicity is a prescription medication that contains dulaglutide, a glucagon-like peptide-1 (GLP-1) receptor agonist. It is primarily used for the management of type 2 diabetes mellitus.
- Type 2 Diabetes Mellitus: Used in conjunction with diet and exercise to improve glycemic control in adults with type 2 diabetes. It can be used alone or with other diabetes medications.
Dulaglutide works by:
- Stimulating Insulin Secretion: In response to meals, it enhances the secretion of insulin, which helps lower blood sugar levels.
- Suppressing Glucagon Release: It reduces the release of glucagon, a hormone that raises blood sugar levels.
- Slowing Gastric Emptying: This leads to a slower absorption of glucose, contributing to improved blood sugar control.
- Dosage: The typical starting dose is 0.75 mg once weekly. If additional glycemic control is needed, the dose may be increased to 1.5 mg once weekly.
- Administration: Trulicity is administered as a subcutaneous injection in the abdomen, thigh, or upper arm. It can be taken at any time of day, with or without food.
Common side effects may include:
- Nausea
- Vomiting
- Diarrhea
- Abdominal pain
- Decreased appetite
- Pancreatitis: There is a risk of pancreatitis; patients should be monitored for symptoms such as severe abdominal pain.
- Kidney Function: Caution is advised in patients with renal impairment, as the use of Trulicity can lead to dehydration.
- Allergic Reactions: Rarely, severe allergic reactions may occur; patients should seek immediate medical attention for symptoms like rash, itching, or swelling.
- Personal or Family History of Medullary Thyroid Carcinoma: Trulicity is contraindicated in patients with a personal or family history of this condition.
- Multiple Endocrine Neoplasia Syndrome Type 2: Should not be used in patients with this syndrome.
- Trulicity may interact with other medications affecting blood sugar levels. It’s important to inform your healthcare provider of all medications and supplements being taken.
- Store Trulicity in the refrigerator until ready for use. It can be kept at room temperature for up to 14 days after removal from the refrigerator. Protect from light.
- Educate patients on how to properly administer the injection and rotate injection sites.
- Discuss the importance of adherence to diet and exercise in conjunction with medication for optimal diabetes management.
- Advise patients to report any unusual side effects, particularly gastrointestinal symptoms or signs of pancreatitis.
Trulicity (Dulaglutide 1.5 mg Injection) is an effective treatment for managing type 2 diabetes, helping to improve blood sugar control through multiple mechanisms. Proper use, monitoring, and patient education are essential for maximizing its benefits. Always consult a healthcare provider for personalized advice and guidance.
Yes! I am InterestedRequest A Callback
Natclovir 500 Mg Injection
Product Price: Rs 1,100 / VialGet Best Price
Product Brochure
Product Details:
| Strength | 500 mg |
| Packaging Type | 10 ml in 1 Vial |
| Composition | Ganciclovir 500mg |
| Brand | Natclovir |
| Manufacturer | Natco Pharma Ltd |
| Treatment | Cytomegalovirus Infection |
Natclovir 500 mg Injection is an antiviral medication primarily used to treat infections caused by certain viruses, particularly herpes viruses. Its active ingredient, acyclovir, is effective in managing infections such as herpes simplex and varicella-zoster virus, making it vital for patients with compromised immune systems.
What is Natclovir?Natclovir contains acyclovir, a synthetic nucleoside analog that inhibits viral DNA synthesis. By targeting viral replication, it helps control the spread of infections, reducing severity and duration.
IndicationsNatclovir is indicated for:
- Herpes Simplex Virus Infections: Effective in treating primary and recurrent infections.
- Varicella-Zoster Virus Infections: Used for the treatment of shingles (herpes zoster) and chickenpox.
- Prophylaxis: It may be used in immunocompromised patients to prevent herpes virus infections.
Natclovir works by:
- Inhibiting Viral DNA Synthesis: It competes with deoxyguanosine triphosphate for incorporation into viral DNA, thereby halting replication.
- Preventing Viral Spread: By inhibiting replication, it reduces the severity and duration of the infection.
- Dosage: The usual adult dose is 500 mg administered intravenously. Dosage may vary based on the type and severity of the infection.
- Administration: Administered slowly via IV infusion to minimize renal toxicity. Hydration during treatment is recommended to prevent kidney damage.
Natclovir is contraindicated in:
- Hypersensitivity: Patients with known allergies to acyclovir or any components of the formulation should avoid it.
- Severe Renal Impairment: Caution is required in patients with kidney issues.
- Renal Function Monitoring: Monitor kidney function during treatment due to potential nephrotoxicity.
- Neurological Effects: Rarely, high doses can lead to neurotoxicity; patients should be monitored for signs of confusion or seizures.
Common side effects may include:
- Nausea and vomiting
- Diarrhea
- Headache
- Fatigue
Serious adverse effects can include:
- Allergic reactions (e.g., rash, difficulty breathing)
- Severe renal impairment
- Neurotoxicity, leading to confusion or seizures
Natclovir may interact with other medications that affect kidney function or are nephrotoxic. Patients should inform their healthcare provider about all medications they are taking.
Storage InstructionsStore Natclovir 500 mg Injection at controlled room temperature, away from light and moisture. Follow specific storage instructions as provided by the manufacturer.
Patient Counseling Information- Advise patients to stay well-hydrated during treatment to minimize kidney risk.
- Discuss potential side effects and when to seek medical attention.
- Emphasize the importance of adhering to the prescribed regimen for optimal effectiveness.
Natclovir 500 mg Injection is a crucial antiviral therapy for managing herpes virus infections. Its ability to inhibit viral replication makes it an essential part of treatment regimens for at-risk patients. Regular monitoring and patient education are vital for achieving the best outcomes.
Yes! I am InterestedRequest A Callback
Cistero 10mg Injection
Product Price: Rs 130 / VialGet Best Price
Product Brochure
Product Details:
| Dose/Strength | 10 mg/10 ml |
| Packaging Size | 10 ml in 1 Vial |
| Composition | Cisplatin 10mg |
| Brand | Cistero 10 |
| Manufacturer | Hetero Drugs Ltd |
| Treatment | Ovarian cancer |
Cistero (Cisplatin) 10 mg Injection is a powerful chemotherapy drug used primarily for the treatment of various types of cancer, including testicular, ovarian, bladder, and lung cancers. As a platinum-based antineoplastic agent, it plays a significant role in modern oncology.
What is Cistero?Cisplatin is a chemotherapy medication that works by interfering with the DNA in cancer cells, preventing them from dividing and growing. This cytotoxic effect makes it an essential treatment option in cancer regimens.
IndicationsCistero is indicated for:
- Testicular Cancer: Often used as part of combination therapy.
- Ovarian Cancer: Effective in treating advanced stages.
- Bladder Cancer: Used in patients with muscle-invasive disease.
- Non-Small Cell Lung Cancer: Frequently part of first-line treatment protocols.
Cistero functions by:
- DNA Cross-Linking: It binds to DNA, forming cross-links that inhibit DNA replication and transcription.
- Inducing Apoptosis: This leads to programmed cell death, particularly in rapidly dividing cancer cells.
- Dosage: The recommended dose for Cistero varies depending on the cancer type and treatment plan. A common regimen may involve a dose of 10 mg/m² administered intravenously.
- Administration: It is crucial that Cistero is administered by a healthcare professional in a controlled setting. The infusion rate and hydration protocols should be carefully followed to minimize side effects.
Cistero is contraindicated in:
- Hypersensitivity: Patients with known allergies to cisplatin or other platinum-containing compounds should not receive this medication.
- Severe Renal Impairment: Caution is advised in patients with significant kidney issues.
- Nephrotoxicity: Monitor renal function closely, as cisplatin can cause significant kidney damage.
- Bone Marrow Suppression: Regular blood counts are essential to detect any drop in blood cell levels.
Common side effects may include:
- Nausea and vomiting
- Decreased appetite
- Fatigue
- Hair loss
Serious side effects can include:
- Severe allergic reactions
- Kidney toxicity
- Electrolyte imbalances (e.g., hypomagnesemia, hypokalemia)
Cistero may interact with other medications, especially those affecting kidney function or myelosuppressive drugs. Patients should inform their healthcare provider about all medications they are taking.
Storage InstructionsStore Cistero 10 mg Injection at room temperature, away from light and moisture. Ensure proper disposal methods are followed to ensure safety.
Patient Counseling Information- Advise patients about the importance of hydration before and after treatment to help protect the kidneys.
- Discuss potential side effects and the importance of reporting any severe reactions.
- Emphasize the need for regular monitoring during treatment.
Cistero 10 mg Injection is a vital component in the treatment of various cancers, utilizing its unique mechanism to halt cancer progression. Effective communication between patients and healthcare providers is crucial for managing treatment and side effects, ensuring the best possible outcomes.
Yes! I am InterestedRequest A Callback
Folitrax 15mg Injection
Product Price: Rs 55 / VialGet Best Price
Product Brochure
Product Details:
| Strength | 15 mg |
| Packaging Size | 1 ml in 1 Ampoule |
| Composition | Methotrexate 15 mg/ml |
| Brand | Folitrax-15 |
| Manufactured by | Cipla |
| Treatment | Rheumatoid joint inflammation |
Folitrax 15 mg Injection contains methotrexate, a potent antimetabolite and immunosuppressant used in the treatment of various conditions, including certain cancers, autoimmune disorders, and ectopic pregnancies. Its ability to inhibit cell proliferation makes it valuable in both oncology and rheumatology.
What is Methotrexate?Methotrexate is a folate antagonist that interferes with DNA synthesis and cellular replication. It works by inhibiting dihydrofolate reductase, an enzyme essential for synthesizing nucleotides required for DNA replication.
IndicationsFolitrax is indicated for:
- Cancer Treatment: Used in high doses for leukemia, lymphoma, and certain solid tumors.
- Rheumatoid Arthritis: Administered in lower doses to manage symptoms and slow disease progression.
- Psoriasis: Reduces the severity of this chronic skin condition.
- Ectopic Pregnancy: Used to terminate early pregnancies occurring outside the uterus.
Methotrexate's mechanism involves:
- Inhibition of Cell Division: Disrupting DNA synthesis prevents the growth of rapidly dividing cancer and inflammatory cells.
- Immunosuppressive Effects: Reduces immune system activity, beneficial in autoimmune conditions.
- Dosage: Typical starting dose for rheumatoid arthritis is 7.5 mg to 15 mg weekly, while cancer treatment may involve higher doses.
- Administration: Folitrax is given as a slow intravenous injection or subcutaneously, depending on the condition treated.
Folitrax is contraindicated in:
- Hypersensitivity: Known allergy to methotrexate or any components of the formulation.
- Severe Liver or Kidney Disease: Avoid in patients with significant renal or hepatic impairment.
- Bone Marrow Suppression: Regular blood tests are essential to monitor cell counts, as methotrexate can lead to myelosuppression.
- Hepatotoxicity: Monitor liver function tests, especially with long-term use.
- Pregnancy and Breastfeeding: Contraindicated during pregnancy and should be avoided in breastfeeding.
Common side effects may include:
- Nausea and vomiting
- Fatigue
- Oral ulcers
- Hair loss
Serious side effects can include:
- Severe allergic reactions
- Pulmonary toxicity
- Liver damage
- Increased risk of infections
Methotrexate may interact with other medications, particularly NSAIDs, certain antibiotics, and those affecting liver function. Patients should inform their healthcare provider about all medications and supplements.
Storage InstructionsStore Folitrax 15 mg Injection at room temperature, protected from light. Follow specific guidelines for preparation and handling to ensure safety.
Patient Counseling Information- Discuss the purpose and potential side effects of Folitrax.
- Emphasize the importance of adhering to the regimen and regular follow-up appointments.
- Advise patients to report any unusual symptoms or side effects, especially signs of infection or liver issues.
Folitrax 15 mg Injection is a critical treatment option for managing cancers and autoimmune diseases. Effective monitoring and communication with healthcare providers are vital to optimize treatment outcomes and minimize potential risks.
Yes! I am InterestedRequest A Callback
Glatira Glatiramer Acetate 20mg Injection
Product Price: Rs 250 / PieceGet Best Price
Product Brochure
Product Details:
| Strength | 20 mg |
| Packaging Size | 7x1 ml |
| Packaging Type | Vial |
| Composition | Glatiramer Acetate 20mg |
| Brand Name | Glatira 20mg |
| Manufactured by | Cipla Ltd |
| Treatment | Multiple sclerosis (MS) |
Overview
Glatira Glatiramer Acetate 20 mg Injection is a disease-modifying therapy indicated for the treatment of relapsing forms of multiple sclerosis (MS). This medication helps manage symptoms and reduce the frequency of relapses, ultimately improving the quality of life for patients living with this chronic neurological condition.
Indications for Use
Glatira is primarily indicated for:
- Relapsing Multiple Sclerosis: Used to reduce the frequency of relapses and delay the progression of disability in patients with clinically isolated syndrome, relapsing-remitting MS, and active secondary progressive MS.
Mechanism of Action
Glatiramer acetate is a synthetic polymer that mimics myelin basic protein, a component of the myelin sheath that surrounds nerve fibers. It works by modulating the immune response, promoting the production of anti-inflammatory cytokines while inhibiting the activation of autoreactive T-cells. This unique mechanism helps to protect nerve fibers from damage and reduces the inflammatory processes associated with MS.
Dosage and Administration
The recommended dosage of Glatira Glatiramer Acetate 20 mg Injection is typically 20 mg administered subcutaneously once daily. Patients should be instructed on proper injection techniques, including site rotation to minimize discomfort and injection site reactions. Regular follow-up with healthcare providers is important to monitor treatment response and adjust therapy as needed.
Potential Side Effects
Common side effects may include:
Injection Site Reactions: Localized pain, redness, swelling, or itching at the injection site.
Flushing: Some patients may experience a sensation of warmth and flushing.
Chest Pain: Temporary chest discomfort can occur but usually resolves quickly.
Nausea: Gastrointestinal discomfort may be reported by some patients.
Serious side effects are rare but can include severe allergic reactions, requiring immediate medical attention.
Storage Instructions
Store Glatira Glatiramer Acetate 20 mg Injection in a refrigerator at 2°C to 8°C (36°F to 46°F). Protect from light and do not freeze. Proper storage is essential to maintain the medication's effectiveness until administration.
Patient Counseling Information
Patients receiving Glatira should be counseled to:
Report Side Effects: Advise patients to notify their healthcare provider of any unusual symptoms or reactions.
Follow Injection Instructions: Ensure patients understand proper injection techniques, including site rotation and hygiene practices.
Attend Regular Check-Ups: Emphasize the importance of follow-up appointments for monitoring disease progression and treatment efficacy.
Conclusion
Glatira Glatiramer Acetate 20 mg Injection is a vital treatment option for individuals with relapsing forms of multiple sclerosis. By modulating the immune response, it helps reduce the frequency of relapses and delay disability progression. Proper administration, ongoing monitoring, and patient education are essential for maximizing treatment benefits and minimizing side effects. Open communication between patients and healthcare providers fosters a comprehensive approach to MS management.
Yes! I am InterestedRequest A Callback
Bevacizumab Injection Abevmy 400mg 16ml Injection
Product Price: Rs 28,500 / VialGet Best Price
Product Brochure
Product Details:
| Strength | 400 mg/16 ml |
| Packaging Type | Vial |
| Brand | Abevmy 400 |
| Packaging Size | 16 ml in 1 Vial |
| Composition | Bevacizumab 400mg/16 ml |
| Manufacturer | Mylan Pharmaceuticals Pvt Ltd |
Bevacizumab Injection (Abevmy 400 mg/16 ml) is a monoclonal antibody used in the treatment of various types of cancer. As an anti-angiogenic agent, it plays a crucial role in inhibiting tumor growth by blocking the formation of blood vessels that supply nutrients to tumors.
What is Bevacizumab?Bevacizumab is a recombinant humanized monoclonal antibody that specifically targets vascular endothelial growth factor (VEGF). By inhibiting VEGF, it prevents the growth of new blood vessels (angiogenesis) that tumors need to grow and spread.
IndicationsAbevmy is indicated for:
- Metastatic Colorectal Cancer: Used in combination with chemotherapy.
- Non-Small Cell Lung Cancer: Administered in combination with other treatments.
- Breast Cancer: Used in certain types of advanced breast cancer.
- Renal Cell Carcinoma: Effective for advanced kidney cancer.
- Cervical Cancer: Indicated for persistent, recurrent, or metastatic cases.
Bevacizumab works by:
- Inhibiting Angiogenesis: By binding to VEGF, it prevents its interaction with its receptors, thereby blocking the signaling pathways that promote blood vessel formation.
- Restricting Tumor Growth: This action effectively starves the tumor of oxygen and nutrients, leading to reduced tumor size and progression.
- Dosage: The typical dose of Abevmy is 5 mg/kg to 10 mg/kg, depending on the cancer type and treatment protocol.
- Administration: Administered via intravenous infusion, with the schedule varying based on specific treatment regimens.
Bevacizumab is contraindicated in:
- Hypersensitivity: Known allergy to bevacizumab or any components of the formulation.
- Uncontrolled Hypertension: Severe hypertension that is not controlled should be managed before treatment.
- Monitor Blood Pressure: Regular monitoring is necessary as bevacizumab can cause hypertension.
- Wound Healing: Caution is advised in patients with recent surgery, as it may impair wound healing.
Common side effects may include:
- Fatigue
- Nausea and vomiting
- Diarrhea
- Headache
Serious side effects can include:
- Severe allergic reactions (anaphylaxis)
- Gastrointestinal perforations
- Hemorrhage (bleeding)
Bevacizumab may interact with other medications, particularly those that affect blood pressure or coagulation. Patients should inform their healthcare provider about all medications they are taking.
Storage InstructionsStore Abevmy 400 mg/16 ml Injection at 2°C to 8°C (36°F to 46°F) in a refrigerator. Protect from light and do not freeze.
Patient Counseling Information- Explain the purpose and administration of bevacizumab.
- Discuss potential side effects and the importance of reporting any unusual symptoms.
- Emphasize the need for regular follow-up appointments to monitor treatment effectiveness and manage side effects.
Bevacizumab Injection (Abevmy 400 mg/16 ml) is a vital component of targeted cancer therapy, offering a mechanism to inhibit tumor growth effectively. Patients should work closely with their healthcare providers to tailor treatment plans that best suit their individual needs.
Yes! I am InterestedRequest A Callback
Neukine 300 Mcg Injection
Product Price: Rs 1,300 / PieceGet Best Price
Product Brochure
Product Details:
| Dose/Strength | 300 mcg |
| Form | Injection |
| Dosage | 300 mcg/1 ml |
| Composition | Filgrastim PFS 300 mcg |
| Brand | Neukine 300 mcg |
| Manufacturer | Intas Pharmaceuticals Ltd |
| Uses | Prevention of Infections after chemotherapy |
Neukine 300 mcg Injection is a recombinant human granulocyte-colony stimulating factor (G-CSF) essential for stimulating white blood cell production, especially neutrophils. This medication is crucial for reducing the risk of infections in patients undergoing chemotherapy, which often leads to neutropenia.
What is Neukine?Neukine mimics natural G-CSF, a protein that regulates neutrophil production in the bone marrow. By enhancing the body’s ability to produce these immune cells, Neukine is indispensable for patients with weakened immune systems, especially those receiving chemotherapy.
IndicationsNeukine is primarily indicated for:
- Chemotherapy-Induced Neutropenia: It lowers the risk of infections during myelosuppressive chemotherapy.
- Bone Marrow Transplantation: Neukine accelerates neutrophil recovery following transplants.
- Congenital Neutropenia: It improves neutrophil counts in patients with chronic neutropenia.
Neukine works by:
- Stimulating Neutrophil Production: It binds to receptors on hematopoietic stem cells in the bone marrow, promoting their proliferation and differentiation into neutrophils.
- Enhancing Neutrophil Function: Neukine increases neutrophil counts and improves their functionality, strengthening the immune response.
- Dosage: Typically, 300 mcg is administered subcutaneously. Individual regimens may vary based on patient needs and chemotherapy type.
- Administration: Usually given once daily, starting 24 hours after chemotherapy until neutrophil counts recover.
Neukine is contraindicated in:
- Hypersensitivity: Patients with known allergies to filgrastim or components of the formulation should avoid this medication.
- Sickle Cell Disease: Caution is advised due to potential complications.
- Bone Pain: Patients may experience bone pain from increased bone marrow activity; appropriate pain management may be needed.
- Splenic Rupture: Rarely reported, but patients should be monitored for abdominal pain.
Common side effects include:
- Bone pain
- Fatigue
- Injection site reactions, such as redness or swelling
Serious effects can include:
- Allergic reactions (e.g., rash, difficulty breathing)
- Splenic rupture (rare)
- Severe respiratory distress
Neukine may interact with other medications affecting bone marrow function. Patients should inform their healthcare provider about all medications they are taking.
Storage InstructionsStore Neukine 300 mcg Injection in the refrigerator at 2°C to 8°C (36°F to 46°F). Do not freeze, and protect it from light. Once removed from refrigeration, it can be stored at room temperature for a limited time.
Patient Counseling Information- Advise patients on the importance of adhering to the treatment schedule and monitoring for side effects.
- Discuss the necessity of reporting severe pain or unusual symptoms.
- Emphasize Neukine's role in reducing infection risk during chemotherapy.
Neukine 300 mcg Injection is a vital therapeutic agent in oncology, mitigating infection risk for chemotherapy patients. Its ability to stimulate neutrophil production underscores its importance in cancer care. Ongoing communication between patients and healthcare providers is essential for optimal treatment outcomes.
Yes! I am InterestedRequest A Callback
Herclon Trastuzumab 440mg Injection
Product Price: Rs 43,500 / VialGet Best Price
Product Brochure
Product Details:
| Strength | 440 mg |
| Packaging Type | 1 Injection in 1 Vial |
| Composition | Trastuzumab 440mg |
| Brand | Herclon 440mg |
| Manufacturer | Trastuzumab 440mg |
| Treatment | Breast cancer,Stomach cancer |
Herclon, containing Trastuzumab, is a monoclonal antibody used in the treatment of HER2-positive cancers. It is particularly effective in targeting specific breast and gastric cancers that overexpress the HER2 protein.
Indications for UseHerclon is indicated for:
- Breast Cancer: Used in the treatment of HER2-positive breast cancer, both in early-stage and metastatic cases.
- Gastric Cancer: Effective in treating HER2-positive gastric or gastroesophageal junction adenocarcinoma, often in combination with chemotherapy.
Trastuzumab works by:
- Binding to HER2 Receptors: It specifically binds to the HER2 protein on cancer cells, blocking signals that promote cell growth.
- Inhibiting Cell Proliferation: This action reduces tumor growth and can induce antibody-dependent cellular cytotoxicity (ADCC), leading to cancer cell death.
- Dosage: The recommended dose of Herclon is typically 440 mg, administered as an intravenous infusion. The dosing schedule may vary based on the specific treatment regimen.
- Administration: Herclon should be administered by a healthcare professional. Close monitoring during infusion is essential to manage potential reactions.
Herclon is contraindicated in:
- Hypersensitivity: Known allergies to Trastuzumab or any components of the formulation.
- Pregnancy: Not recommended for use during pregnancy due to potential harm to the fetus.
- Cardiotoxicity: Patients should be monitored for signs of heart problems, particularly if they have a history of cardiac issues.
- Infusion Reactions: Observe for allergic reactions during and after administration; premedication may be necessary in some cases.
- Monitoring: Regular monitoring of heart function is recommended throughout treatment.
Common side effects may include:
- Fever and chills
- Nausea
- Fatigue
- Headache
- Injection site reactions
Serious adverse effects can include:
- Severe allergic reactions (anaphylaxis)
- Cardiac dysfunction, including heart failure
- Lung problems, such as interstitial pneumonia
Trastuzumab may interact with other medications, especially those affecting heart function. Patients should inform their healthcare provider about all medications they are taking, including over-the-counter drugs.
Storage InstructionsStore Herclon (Trastuzumab) 440 mg Injection in a refrigerator at 2°C to 8°C (36°F to 46°F). Protect from light and do not freeze.
Patient Counseling Information- Report Side Effects: Advise patients to notify their healthcare provider of any unusual reactions or symptoms.
- Monitor Heart Health: Encourage patients to report any symptoms of heart problems, such as shortness of breath or swelling.
- Lifestyle Adjustments: Discuss ways to manage common side effects and improve overall well-being.
Herclon (Trastuzumab) 440 mg Injection is an essential treatment option for HER2-positive breast and gastric cancers. Proper management, monitoring, and patient education are crucial for optimizing treatment outcomes and minimizing adverse effects. Open communication between patients and healthcare providers is vital for successful cancer management.
Yes! I am InterestedRequest A Callback
View More